<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEE SCHEDULE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

25. Accounting And Appropriation Data

26. Total Award Amount (For Govt. Use Only)

$2,628,000,000.00
SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEM

Offeror To Complete Block 12, 17, 23, 24, & 30

2. Contract No. W15QKN-21-C-0014
3. Award/Effective Date 2021JAN12
4. Order Number
5. Solicitation Number
6. Solicitation Issue Date

7. For Solicitation Information Call:
   A. Name [29]
   B. Telephone Number (No Collect Calls) [44]

8. Offer Due Date/Local Time

9. Issued By
   Code W15QKN
   ARMY CONTRACTING COMMAND - NJ
   PICATINNY ARSENAL, NJ 07806-5000

10. This Acquisition is
    Unrestricted OR Set Aside: % For:
        □ Small Business
        □ Women-Owned Small Business (WOSB) Eligible Under the Women-Owned Small Business Program
        □ Hubzone Small Business
        □ EDWOSB
        □ Service-Disabled Veteran-Owned Small Business

11. Delivery For FOB Destination
    □ See Schedule

12. Discount Terms

13a. This Contract Is A Rated Order Under DPAS (15 CFR 700)
13b. Rating NONE

14. Method Of Solicitation
    □ RFQ
    □ IFB
    □ X RFP

15. Deliver To
    Code W15QKN
    SEE SCHEDULE

16. Administered By
    Code W15QKN
    ACC NJ BLDG 10 PRIPPS RD
    PICATINNY ARSENAL, NJ 07806-5000

17a. Contractor/Offeror Code 54472
    Facility REGENERON PHARMACEUTICALS, INC.
    777 OLD SALEM MILL RIVER RD
    TARRYTOWN, NY 10591-6717

17b. Telephone No.

18a. Payment Will Be Made By
    Code HQ0490
    DFAS-INDY VP GFEBS
    8899 E. 56TH STREET
    INDIANAPOLIS IN 46249-3800

18b. Submit Invoices To Address Shown In Block 18a Unless Block Below Is Checked

19. Item No.

20. Schedule Of Supplies/Services
    SEE SCHEDULE

21. Quantity

22. Unit

23. Unit Price

24. Amount

(Use Reverse and/or Attach Additional Sheets As Necessary)

25. Accounting And Appropriation Data
    SEE CONTRACT ADMINISTRATION DATA

26. Total Award Amount (For Govt. Use Only) $2,625,000,000.00

27a. Solicitation Incorporates By Reference FAR 52.212-1, 52.212-4. FAR 52.212-3 And 52.212-5 Are Attached. Addenda □ Are □ Are Not Attached.
27b. Contract/Purchase Order Incorporates By Reference FAR 52.212-4. FAR 52.212-5 Is Attached. Addenda □ Are □ Are Not Attached.

28. Contractor Is Required To Sign This Document And Return 2 Copies to Issuing Office. Contractor Agrees To Furnish And Deliver All Items Set Forth Or Otherwise Identified Above And On Any Additional Sheets Subject To The Terms And Conditions Specified.

29. Award Of Contract: Ref. Offer Dated ________, Your Offer On Solicitation (Block 5), Including Any Additions Or Changes Which Are Set Forth Herein, Is Accepted As To Items:

30a. Signature Of Offeror/Contractor
    /SIGNED/
    Authorized For Local Reproduction
    Previous Edition Is Not Usable

30b. Name And Title Of Signer (Type Or Print) 30c. Date Signed

31a. United States Of America (Signature Of Contracting Officer)
    /SIGNED/
    Standard Form 1449 (Rev. 2/2012)
    Prescribed By GSA-FAR (48 CFR) 53.212

31b. Name Of Contracting Officer (Type Or Print) 31c. Date Signed

Authorized For Local Reproduction
Previous Edition Is Not Usable
|-------------|---------------------------------|-------------|---------|----------------|----------|

32a. Quantity In Column 21 Has Been

Received [ ]
Inspected [ ]
Accepted, And Conforms To The Contract, Except As Noted: [ ]

32b. Signature Of Authorized Government Representative

32c. Date

32d. Printed Name and Title of Authorized Government Representative

32e. Mailing Address of Authorized Government Representative

32f. Telephone Number of Authorized Government Representative

32g. E-Mail of Authorized Government Representative

33. Ship Number

34. Voucher Number

35. Amount Verified Correct For

36. Payment

COMPLETE [ ]
PARTIAL [ ]
FINAL [ ]

37. Check Number

38. S/R Account No.

39. S/R Voucher Number

40. Paid By

41a. I Certify This Account Is Correct And Proper For Payment

41b. Signature And Title Of Certifying Officer

41c. Date

42a. Received By (Print)

42b. Received At (Location)

42c. Date Rec’d (YY/MM/DD) [ ]

42d. Total Containers

Standard Form 1449 (Rev. 2/2012) Back
Executive Summary

1. Background: The Department of Health and Human Services (DHHS) continuously monitors emerging infectious disease risk and prepares to respond to the threat of novel emerging infectious disease outbreaks in the United States. DHHS is responding to an outbreak of respiratory disease caused by a novel coronavirus that was first detected in China, and which has now spread worldwide, including in the United States. The virus has been named SARS-CoV-2 and the disease it causes has been named Coronavirus Disease 2019 (abbreviated COVID-19).

On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC). On January 31, Health and Human Services Secretary Alex M. Azar II declared a Public Health Emergency (PHE) for the United States to aid the nation’s healthcare community in responding to COVID-19. On March 11, WHO publicly characterized COVID-19 as a pandemic. On March 13, the President of the United States declared the COVID-19 outbreak a national emergency.

In July 2020, the Department of Defense (DoD) awarded an Other Transaction Agreement (OTA) under the authority 10 USC 2371b to Regeneron to manufacture and sell drug product to the Government, and to distribute such drug product for the Government in the U.S. These manufacturing production activities included manufacturing at-scale, filling and finishing, and storage and shipping of REGN10987 and REGN10933 as a therapeutic cocktail (casirivimab and imdevimab) to treat COVID-19 infected patients. On November 21, 2020, Regeneron announced that the antibody cocktail casirivimab and imdevimab administered together, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

2. Contract Description: The U.S Army Contracting Command – New Jersey (CCNJ), on behalf of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Biomedical Advanced Research and Development Authority (BARDA), will execute a contract for the procurement of up to 1,250,000 doses of the EUA authorized (or BLA approved) casirivimab and imdevimab therapeutic, enough to treat much of the targeted US population currently or projected to be infected over the coming months. This contract award is a sole-source Firm Fixed Price (FFP) contract pursuant to FAR 6.302-2, “Unusual and Compelling Urgency,” to Regeneron Pharmaceuticals, Inc., Tarrytown, New York. This action has a total FFP value of $2,625,000,000.00. The price per dose is inclusive of storage, distribution, insurance and administration costs, costs associated with obtaining and maintaining regulatory authorization for the product (packaging, labeling, and informational materials), and Regeneron’s manufacturing facilities. The period of performance for this contract is twelve (12) months, to include distribution of the product.

3. The Representations and Certifications made by Regeneron in the System for Award Management (SAM) are hereby incorporated into this contract by reference.

4. The Regeneron Draft Small Business Subcontracting Plan, dated 30 November 2020, is hereby incorporated into this contract by attachment. It is noted that this draft plan will be replaced by the plan that is ultimately approved by the United States Department of Veterans Affairs.

5. Contract Point of Contact:
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

*** END OF NARRATIVE A0001 ***
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>SUPPLIES OR SERVICES AND PRICES/COSTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COVID THERAPEUTIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NSN: 9999-99-9999</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0001AA</td>
<td>COVID-19 THERAPEUTIC (REGN10987 AND REGN10933)</td>
<td>02(4)</td>
<td>EA</td>
<td>$2,100.0000</td>
<td>$2,100.0000</td>
</tr>
<tr>
<td></td>
<td>COMMODITY NAME: COVID THERAPEUTIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CLIN CONTRACT TYPE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Firm Fixed Price</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRON: CB1RD13635</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRON AMD: 01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACRN: AA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Packaging and Marking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inspection and Acceptance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INSPECTION: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACCEPTANCE: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deliveries or Performance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOB POINT: Destination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SHIP TO:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(75A501) OFFICE OF ACQ MGMT POLICY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HUBERT HUMPHREY BLDG 200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INDEPENDENCE AVENUE SW ROOM 336E</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WASHINGTON,DC,20201</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The parties will coordinate ordering through</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>centralized distribution via the established</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Memorandum of Understanding between Regeneron, ASPR,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>and AmerisourceBergen. Exact ship-to locations for</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>product will be identified through this coordinated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>process.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(End of narrative F001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0001AB</td>
<td>COVID-19 THERAPEUTIC (REGN10987 AND REGN10933)</td>
<td>02(4)</td>
<td>EA</td>
<td>$2,100.0000</td>
<td>$2,100.0000</td>
</tr>
<tr>
<td></td>
<td>COMMODITY NAME: COVID THERAPEUTIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CLIN CONTRACT TYPE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Firm Fixed Price</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

<table>
<thead>
<tr>
<th>ITEM NO</th>
<th>SUPPLIES/SERVICES</th>
<th>QUANTITY</th>
<th>UNIT</th>
<th>UNIT PRICE</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001AC</td>
<td>PRON: CB1RD14381</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRON AMD: 01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACRN: AB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSC: 6505</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Packaging and Marking

Inspection and Acceptance

INSPECTION: Destination

ACCEPTANCE: Destination

Deliveries or Performance

<table>
<thead>
<tr>
<th>DOC</th>
<th>SUPPL</th>
</tr>
</thead>
<tbody>
<tr>
<td>REL CD</td>
<td>MILSTRIP</td>
</tr>
<tr>
<td>001</td>
<td>WS6XNH10011002</td>
</tr>
</tbody>
</table>

DEL REL CD: 001

QUANTITY: 3

DEL DATE: 3

FDP POINT: Destination

SHIP TO:

(75A501) OFFICE OF ACQ MGMT POLICY

HUBERT HUMPHREY BLDG 200

INDEPENDENCE AVENUE SW ROOM 336E

WASHINGTON, DC, 20201

The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen. Exact ship-to locations for product will be identified through this coordinated process.

(End of narrative F001)

---

0001AC

COVID-19 THERAPEUTIC (REGN10987 AND REGN10931)

COMMODITY NAME: COVID THERAPEUTIC

CLIN CONTRACT TYPE:

Firm Fixed Price

PRON: CB1RD41544

PRON AMD: 01

ACRN: AC

PSC: 6505

Packaging and Marking

Inspection and Acceptance

INSPECTION: Destination

ACCEPTANCE: Destination

Deliveries or Performance

<table>
<thead>
<tr>
<th>DOC</th>
<th>SUPPL</th>
</tr>
</thead>
<tbody>
<tr>
<td>REL CD</td>
<td>MILSTRIP</td>
</tr>
<tr>
<td>001</td>
<td>WS6XNH10011003</td>
</tr>
</tbody>
</table>

DEL REL CD: 001

QUANTITY: 3

DEL DATE: 3

FDP POINT: Destination

SHIP TO:

(75A501) OFFICE OF ACQ MGMT POLICY

HUBERT HUMPHREY BLDG 200

INDEPENDENCE AVENUE SW ROOM 336E

WASHINGTON, DC, 20201

The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen. Exact ship-to locations for product will be identified through this coordinated process.

(End of narrative F001)
The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen. Exact ship-to locations for product will be identified through this coordinated process.

(End of narrative F001)

The ELIN below is associated with the Data Item numbers in the Contract Data Requirements List (CDRL, DD 1423), in Section J. Reference individual CDRLs for applicable instructions and delivery dates.

(End of narrative A001)
On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the extension to the delivery schedule, the contractor shall coordinate with the Government to determine an appropriate path forward, emerging infectious disease outbreaks in the United States. DHHS is responding to an outbreak of respiratory disease caused by a novel drug product to the Government, and to distribute such drug product for the Government in the U.S. These manufacturing production and national emergency response to the Coronavirus Disease 2019 (COVID-19), requires the production of Regeneron therapeutic cocktail REGN10987 and REGN10933 (casirivimab and imdevimab) on a commercial item basis, up to 1,250,000 doses to treat members of the DoD and the general population infected with the SARS-CoV-2 Virus.

C.1.1 Background: The DHHS continuously monitors emerging infectious disease risk and prepares to respond to the threat of novel emerging infectious disease outbreaks in the United States. DHHS is responding to an outbreak of respiratory disease caused by a novel coronavirus that was first detected in China, and which has now spread worldwide, including in the United States. The virus has been named SARS-CoV-2 and the disease it causes has been named Coronavirus Disease 2019 (abbreviated COVID-19).

On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC). On January 31, Health and Human Services Secretary Alex M. Azar II declared a Public Health Emergency (PHE) for the United States to aid the nations healthcare community in responding to COVID-19. On March 11, WHO publicly characterized COVID-19 as a pandemic. On March 13, the President of the United States declared the COVID-19 outbreak a national emergency.

In July 2020, the DoD awarded an Other Transaction Agreement under the authority of 10 USC 2371b to Regeneron to manufacture and sell drug product to the Government, and to distribute such drug product for the Government in the U.S. These manufacturing production activities included manufacturing at-scale, filling and finishing, and storage and shipping of REGN10987 and REGN10933 as a therapeutic cocktail to treat COVID-19 infected patients. On November 21, 2020, Regeneron announced that the antibody cocktail casirivimab and imdevimab administered together, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). As part of DHHS preparedness and response activities, DHHS seeks to purchase up to 1,250,000 doses of the EUA authorized (or Biologics License Application (BLA) approved) casirivimab and imdevimab therapeutic, enough to treat much of the targeted US population currently or projected to be infected over the coming months.

C.2 Objectives and Quantity: The contractor shall produce up to 1,250,000 doses of therapeutic, and the Government will purchase all such doses available in Vendor-Managed Inventory (VMI) by the applicable date set forth below:

No Later Than (NLT) June 30, 2021. The Government will consider extending the time for delivery to NLT September 30, 2021, if the contractor is unable to complete delivery to VMI by June 30, 2021, after making a good faith effort to do so. However, prior to any extension to the delivery schedule, the contractor shall coordinate with the Government to determine an appropriate path forward, aligning with Government needs. The contractor shall comply with the procedures of FAR 52.212-4(f), Excusable Delays.

C.3 Requirements:

C.3.1 Therapeutic: The contractor shall distribute the product to Government designated sites as directed by the Government. EUA authorized finished drug product in vials in accordance with the products storage and handling requirements in the EUA, including temperature controls. This shall include storage and distribution activities. Regeneron will engage one or more third party providers (each a Distributor) to perform storage and distribution activities for drug product at the direction of the Government. The Government will be solely responsible for all allocation determinations related to drug product, including allocation to end users and communication of such allocation determinations to the Distributor. Unless otherwise mutually agreed upon by the parties, drug product shall be shipped to the Government or distributed, as applicable, solely within the United States (including its territories and possessions). The contractor shall [Redacted] until the product is distributed to the end user (e.g., the hospital, infusion center or other end-user). To the extent that Regeneron is responsible for the correction, repair or replacement of Government property held in vendor-managed inventory or in distribution and in the possession of the Distributor, [Redacted], the Government will [Redacted] of such property. The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, Assistant Secretary for Preparedness and Response (ASPR), and AmerisourceBergen. Storage and distribution activities under the EUA shall be supported under this agreement through the end of the period of performance.

C.3.2 Product Development Manufacturing Reports and Projections: Regeneron will provide manufacturing reports and manufacturing dose tracking projections/actuals, in the format and having the content mutually agreed upon by the Government and Regeneron. Regeneron will update the reports during manufacturing campaigns and upon manufacturing deliverable submission during COVID-19 response operations (where a Public Health Emergency has been declared), with the first deliverable submission within 30 days of award. For clarity, the reports described in this section apply to Formulated Drug Substance and Drug Product prior to delivery and acceptance by the Government. Tracking reports for product following delivery and acceptance, shall be set forth in the Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen.
C.4 Reporting: The contractor shall provide the following reports/deliverables in accordance with Exhibit A:

CDRL # Title
A001 Post Award Teleconference Minutes
A002 Kickoff Meeting Agenda and Minutes
A003 Teleconference Minutes
A004 Quarterly Meetings
A005 FDA Meeting Minutes
A006 Daily Check-in with Project Staff for COVID-19 Agreement
A007 Monthly Progress Reports
A008 Milestone Reports
A009 Draft Technical Progress Report
A010 Final Technical Progress Report
A011 Product Development Source Material and Manufacturing Report
A012 Contractor Locations
A013 Pandemic Management Plan
A014 Supply Chain and Distribution Tracking
A015 Distribution Plan
A016 Manufacturing Development Plan
A017 Quality Management Plan
A018 Quality Agreement
A019 Release Documentation for Doses to be Delivered
A020 Manufacturing and Distribution Records
A021 Security Plan
A022 Supply Chain Resiliency Plan
A023 Manufacturing Data Requirements
A024 BARDA Audit
A025 FDA Inspections
A026 QA Audits
A027 FDA Submissions
A028 EUA Filing
A029 Provision of Public Law 115-92 SPONSOR Authorization Letter
A030 Press Releases

C.5 Period of Performance: The period of performance for this contract is twelve (12) months.

C.6 Inspection/Acceptance:

C.6.1 Inspection: The Technical Point of Contact (TPOC) is a duly authorized representative of the Government, and is responsible for the inspection and/or acceptance of all items/activities to be delivered and/or completed under this contract. The parties acknowledge that acceptance may depend on the compliance with FDA regulations at 21 CFR 600-680 regarding the BLA, current Good Manufacturing Practice (cGMP) regulations at 21 CFR 210, 211, and other FDA regulations.

C.6.2 Acceptance: Title to drug product will pass to the Government upon delivery of such drug product to VMI, and the Government’s corresponding written acceptance of such drug product. The Government shall accept product that conforms to contract requirements based on a Certificate of Analysis (COA) and any other quality documentation required to be provided by Regeneron, as set forth in the Quality Agreement (“Required Documents”), and the parties shall perform their obligations relating to product delivery set forth in the applicable Quality Agreement for the product. The Government’s acceptance of drug product will be [504] [505] provide written notice of acceptance or rejection within [727] [728] . Any visibly damaged product will be rejected immediately. The contractor will transfer product from VMI to the Distributor for distribution directed by the Government; provided that, product shall not be provided to the Distributor until it is accepted by the Government. The contractor shall provide a shipment temperature tracking report within [504] [505] of contractors receipt of such report from its storage vendor, or otherwise in accordance with the applicable Quality Agreement. Any product subject to a temperature excursion outside of acceptable tolerances, shall be rejected. Any rejected product shall be returned to the contractor or otherwise disposed of according to contractor instructions. The Government will not be obligated to pay for rejected vials, nor will rejected vials count toward the delivery requirement. The contractor shall establish a notification mechanism for delivery sites to contact the Government regarding rejected vials.

C.7 Packaging and Marking: The contractor shall label product according to FDA guidelines/instructions. Packaging shall be in shipping containers according to the contractors standard commercial practice.

C.8 Delivery of Authorized or Approved Doses: The contractors delivery obligations under this contract are contingent on product being covered by an EUA or marketing approval issued by the FDA in effect on the date of delivery. For the purpose of this contract, a dose will constitute the lowest dose authorized or approved by the FDA for the treatment of high-risk adult and pediatric patients aged 12 years and older with recently diagnosed mild-to-moderate coronavirus disease (COVID-19) prior to or on the date of delivery. Except as
otherwise mutually agreed to by the parties, the product shall not be sold to the Government for use in any other approved or authorized indication or dose exceeding 2400mg/mAb.

Public Disclosures: Notwithstanding any other provision in this contract, the contractor may publicly release any information related to this contract without prior approval to the extent necessary to satisfy or address regulatory requirements, contractual obligations to third parties, and the public interest in data about the safety or efficacy of the product.

Public Readiness and Emergency Preparedness (PREP) Act: The Government will ensure that no product purchased under this contract is used outside the United States (including its territories or possessions) or in a way that is not protected from liability by a declaration issued under the PREP Act that is active at the time of use.

C.9 Government Technical Point of Contact:

<table>
<thead>
<tr>
<th>Name</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSH BARDA</td>
<td>1234567890</td>
<td><a href="mailto:hsh@barda.gov">hsh@barda.gov</a></td>
</tr>
</tbody>
</table>

*** END OF NARRATIVE C0001 ***
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

<table>
<thead>
<tr>
<th>Regulatory Cite</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>52.246-2</td>
<td>INSPECTION OF SUPPLIES--FIXED-PRICE</td>
<td>AUG/1996</td>
</tr>
<tr>
<td>52.246-16</td>
<td>RESPONSIBILITY FOR SUPPLIES</td>
<td>APR/1984</td>
</tr>
</tbody>
</table>
Any deliverables identified within this section are only required to be delivered should they differ from what has been previously delivered under Regeneron's prototype agreement, MCD2008-005.

I. Supply Chain Resiliency Plan

A. The contractor shall develop and submit within (30) days of contract award, a comprehensive Supply Chain Resiliency Program that provides identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods.

a) A critical component is defined as any material that is essential to the product or the manufacturing process associated with that product. Included in the definition are consumables and disposables associated with manufacturing. NOT included in the definition are facility and capital equipment.

B. Consideration of critical components includes the evaluation and potential impact of raw materials, excipients, active ingredients, substances, pieces, parts, software, firmware, labeling, assembly, testing, analytical and environmental componentry, reagents, or utility materials which are used in the manufacturing of a drug, cell banks, seed stocks, devices and key processing components and equipment. A clear example of a critical component is one where a sole supplier is utilized.

C. The contractor shall identify key equipment suppliers, their locations, local resources, and the associated control processes at the time of award. The Supply Chain Resiliency Plan shall address planning and scheduling for active pharmaceutical ingredients, upstream, downstream, component assembly, finished drug product and delivery events as necessary for the delivery of product.

a) Communication for these requirements shall be updated as part of an annual review, or as necessary, as part of regular contractual communications.

b) For upstream and downstream processing, both single-use and re-usable in-place processing equipment, and manufacturing disposables also shall be addressed. For finished goods, the inspection, labeling, packaging, and associated machinery shall be addressed taking into account capacity capabilities.

c) The focus on the aspects of resiliency shall be on critical components and aspects of complying with the contractual delivery schedule. Delivery methods shall be addressed, inclusive of items that are foreign-sourced, both high and low volume, which would significantly affect throughput and adherence to the contractually agreed deliveries.

D. The contractor shall articulate in the plan, the contractors methodology for inventory control, production planning, scheduling processes and ordering mechanisms, as part of those agreed deliveries.

a) Production rates and lead times shall be understood and communicated to the Contracting Officer (CO) or the Technical Point of Contact (TPoC) as necessary.

b) Production throughput critical constraints should be well understood by activity and by design, and communicated to contractual personnel. As necessary, communication should focus on identification, exploitation, elevation, and secondary constraints of throughput, as appropriate.

E. Reports for critical items shall include the following information:
   a) Critical Material
   b) Vendor
   c) Supplier, Manufacturing / Distribution Location
   d) Supplier Lead Time
   e) Shelf Life
   f) Transportation / Shipping Restrictions

F. The CO and TPOC reserve the right to request un-redacted copies of technical documents provided in response to this section, during the period of performance, for distribution within the Government. Documents shall be provided within (30) days after CO issues the request. The contractor may arrange for additional time if deemed necessary, and agreed to by the CO.

II. Manufacturing Data Requirements

A. The contractor shall submit within (30) days of contract award, detailed data regarding project materials, sources, and manufacturing sites, including but not limited to physical locations of sources of raw and processed material by type of material;
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

location and nature of work performed at manufacturing, processing, and fill/finish sites; and location and nature of clinical studies sites (it being understood that such information already has been provided). The Government may provide a table in tabular format for the contractor to be used to submit such data, which would include but not be limited to the following:

a) Storage/inventory of ancillary materials (vials, needles, syringes, etc.)
b) Shipment of ancillary materials (vials, needles, syringes, etc.)
c) Disposal of ancillary materials (vials, needles, syringes, etc.)
d) Seed development or other starting material manufacturing
e) Bulk drug substance and/or adjuvant production
f) Fill, finish, and release of product or adjuvant
g) Storage/inventory of starting materials, bulk substance, or filled/final product or adjuvant
h) Stability information of bulk substance and/or finished product
i) Shipment of bulk substance of final product
j) Disposal of bulk substance or final product

III. Product Development Source Material and Manufacturing Reports and Projections

A. The contractor shall submit a detailed spreadsheet regarding critical project materials that are sourced from a location other than the United States, sources, and manufacturing sites, including but not limited to: physical locations of sources of raw and processed material type of material; location and nature of work performed at manufacturing sites; and location and nature of clinical studies sites.

B. The contractor will provide manufacturing reports and manufacturing dose tracking projections/actuals utilizing the "COVID-19 Dose Tracking Templates," on any contract/agreement that is manufacturing product.

C. Reporting Procedures and Due Dates:

1. Contractor will submit Product Development Source Material Report:
   a) Within [x] of contract award
   b) Within [x] of substantive changes made to sources and/or materials
   c) On the [x] contract anniversary, if no substantive changes have been made in the preceding [x] period

2. The Government will provide written comments to the Product Development Source Material and Manufacturing Report within [x] after the submission.
   a) If corrective action is recommended, the contractor must address all concerns raised by the Government in writing.

3. Product Development and Source Material report to be submitted via spreadsheet; Dose Tracking can be completed via spreadsheet or other format (e.g. XML or JSON) as agreed to by the Government and contractor.

4. The contractor will update the Dose Tracking Template weekly during manufacturing campaigns and upon manufacturing deliverable submission during COVID-19 response operations (where a Public Health Emergency has been declared), with the first deliverable submission within [x] of award.

IV. Contractor Locations

A. The contractor shall submit detailed data regarding locations where work will be performed under this contract, including addresses, points of contact, and work performed per location, to include sub-contractors.

The contractor will submit Work Locations Report:

1. Contractor will submit Work Locations Report:
   a) Within [x] of contract award
   b) Within [x] after a substantive location or capabilities change
   c) Within [x] of a substantive change if the work performed supports medical countermeasure development that addresses a threat that has been declared a Public Health Emergency by the HHS Secretary or a Public Health Emergency of International Concern by the WHO

V. Access and General Protection/Security Policy and Procedures

This standard language text is applicable to ALL employees working on critical information related to Operation Warp Speed (OWS) with an area of performance within a Government controlled installation, facility or area. Employees shall comply with applicable installation, facility and area commander installation/facility access and local security policies and procedures (provided by government representative). The performer also shall provide all information required for background checks necessary to access critical information related to OWS, and to meet Government installation access requirements to be accomplished by installation Director of
Emergency Services or Security Office. The workforce must comply with all personnel identity verification requirements as directed by the Government and/or local policy. In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OHS change, the Government may require changes in performer security matters or processes. In addition to the industry standards for employment background checks, the contractor must be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States Government.

VI. Operational Security (OPSEC)

The performer shall develop an OPSEC Standard Operating Procedure (SOP)/Plan within [30](4) of project award to be reviewed and approved by the responsible Government OPSEC officer. This plan will be submitted to the TPOC for coordination of approvals. This SOP/Plan will include identifying the critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.

VII. Security Plan

The contractor shall develop a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the Government requirement. This plan shall establish security practices and procedures that demonstrate how the contractor will meet and adhere to the security requirements outlined below prior to the commencement of product manufacturing, and shall be delivered to the Government within [30](4) of award. The contractor shall also ensure all subcontractors, consultants, researchers, etc. performing work on behalf of this effort, comply with all Government security requirements and prime contractor security plans.

a) The Government will review in detail and submit comments within [30](4) to the CO to be forwarded to the contractor. The contractor shall review the Draft Security Plan comments, and, submit a Final Security Plan to the U.S. Government within [30](4) after receipt of the comments.

b) The Security Plan shall include a timeline for compliance of all the required security measures outlined by the Government.

c) Upon completion of initiating all security measures, the contractor shall supply to the CO a letter certifying compliance to the elements outlined in the Final Security Plan.

At a minimum, the Final Security Plan shall address the following items:

Security Requirements:

1. Facility Security Plan

Description: As part of the partner facility’s overall security program, the contractor shall submit a written security plan with their proposal to the Government for review and approval by Government security subject matter experts. The performance of work under the contract will be in accordance with the approved security plan. The security plan will include the following processes and procedures at a minimum:

A. Security Administration
- organization chart and responsibilities
- written security risk assessment for site
- threat levels with identification matrix (High, Medium, or Low)
- enhanced security procedures during elevated threats
- liaison procedures with law enforcement
- annual employee security education and training program

B. Personnel Security
- policies and procedures
- candidate recruitment process
- background investigations process
- employment suitability policy
- employee access determination
- rules of behavior/conduct
- termination procedures
- non-disclosure agreements

C. Physical Security Policies and Procedures
- internal/external access control
- protective services
- identification/badging
- employee and visitor access controls
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

- parking areas and access control
- perimeter fencing/barriers
- product shipping, receiving and transport security procedures
- facility security lighting
- restricted areas
- signage
- intrusion detection systems
- alarm monitoring/response
- closed circuit television
- product storage security
- other control measures as identified

D. Information Security
- identification and marking of sensitive information
- access control
- storage of information
- document control procedures
- retention/destruction requirements

E. Information Technology/Cyber Security Policies and Procedures
- intrusion detection and prevention systems
- threat identification
- employee training (initial and annual)
- encryption systems
- identification of sensitive information/media
- password policy (max days 90)
- lock screen time out policy (minimum time 20 minutes)
- removable media policy
- laptop policy
- removal of IT assets for domestic/foreign travel
- access control and determination
- VPN procedures
- WiFi and Bluetooth disabled when not in use
- system document control
- system backup
- system disaster recovery
- incident response
- system audit procedures
- property accountability

2. Site Security Master Plan

Description: The partner facility shall provide a site schematic for security systems which includes: main access points; security cameras; electronic access points; IT Server Room; Product Storage Freezer/Room; and bio-containment laboratories.

3. Site Threat/Vulnerability/Risk Assessment

Description: The partner facility shall provide a written risk assessment for the facility addressing: criminal threat, including crime data; foreign/domestic terrorist threat; industrial espionage; insider threats; natural disasters; and potential loss of critical infrastructure (power/water/natural gas, etc.) This assessment shall include recent data obtained from local law enforcement agencies. The assessment should be updated annually.

4. Physical Security

A. Closed Circuit Television (CCTV) Monitoring

a) Layered (internal/external) CCTV coverage with time-lapse video recording for buildings and areas where critical assets are processed or stored.
b) CCTV coverage must include entry and exits to critical facilities, perimeters, and areas within the facility deemed critical to the execution of the contract.
c) Video recordings must be maintained for a minimum of 30 days.
d) CCTV surveillance system must be on emergency power backup.

B. Facility Lighting
a) Lighting must cover facility perimeter, parking areas, critical infrastructure, and entrances and exits to buildings.
b) Lighting must have emergency power backup.
c) Lighting must be sufficient for the effective operation of the CCTV surveillance system during hours of darkness.

C. Shipping and Receiving
   a) Must have CCTV coverage and an electronic access control system.
   b) Must have procedures in place to control access and movement of drivers picking up or delivering shipments.
   c) Must identify drivers picking up Government products by government issued photo identification.

D. Access Control
   a) Must have an electronic intrusion detection system with centralized monitoring.
   b) Responses to alarms must be immediate and documented in writing.
   c) Employ an electronic system (i.e., card key) to control access to areas where assets critical to the contract are located
      (facilities, laboratories, clean rooms, production facilities, warehouses, server rooms, records storage, etc.).
   d) The electronic access control should signal an alarm notification of unauthorized attempts to access restricted areas.
   e) Must have a system that provides a historical log of all key access transactions and kept on record for a minimum of
      [redacted]...months.
   f) Must have procedures in place to track issuance of access cards to employees and the ability to deactivate cards when they are lost
      or an employee leaves the company.
   g) Response to electronic access control alarms must be immediate and documented in writing and kept on record for a minimum of
      [redacted]...months.
   h) Should have written procedures to prevent employee piggybacking access.
   i) Critical infrastructure (generators, air handlers, fuel storage, etc.) should be controlled and limited to those with a legitimate
      need for access.
   j) Must have a written manual key accountability and inventory process.
   k) Physical access controls should present a layered approach to critical assets within the facility.

E. Employee/Visitor Identification
   a) Should issue company photo identification to all employees.
   b) Photo identification should be displayed above the waist anytime the employee is on company property.
   c) Visitors should be sponsored by an employee and must present government issued photo identification to enter the property.
   d) Visitors should be logged in and out of the facility and should be escorted by an employee while on the premises at all times.

F. Security Fencing
Requirements for security fencing will be determined by the criticality of the program, review of the security plan, threat assessment,
and onsite security assessment.

G. Protective Security Forces
Requirements for security officers will be determined by the criticality of the program, review of the security plan, threat assessment,
and onsite security assessment.

H. Protective Security Forces Operations
   a) Must have in-service training program.
   b) Must have Use of Force Continuum.
   c) Must have communication systems available (i.e., landline on post, cell phones, handheld radio, and desktop computer).
   d) Must have Standing Post Orders.
   e) Must wear distinct uniform identifying them as security officers.

I. Security Operations
   a) Establish formal liaison with law enforcement.
   b) Meet in person at a minimum annually. Document meeting notes and keep them on file for a minimum of [redacted].
      POC information for LE Officer that attended the meeting must be documented.
   c) Implement procedures for receiving and disseminating threat information.

B. Training
   a) Conduct new employee security awareness training.
b) Conduct and maintain records of annual security awareness training.

C. Security Management

a) Designate a knowledgeable security professional to manage the security of the facility.
b) Ensure subcontractor compliance with all Government security requirements.

6. Personnel Security

A. Records Checks

Verification of social security number, date of birth, citizenship, education credentials, five-year previous employment history, five-year previous residence history, FDA disbarment, sex offender registry, credit check based upon position within the company; motor vehicle records check as appropriate; and local/national criminal history search.

B. Hiring and Retention Standards

a) Detailed policies and procedures concerning hiring and retention of employees, employee conduct, and off-boarding procedures.
b) Off-boarding procedures should be accomplished within 24 hours of employees leaving the company. This includes termination of all network access.

7. Information Security

A. Physical Document Control

a) Applicable documents shall be identified and marked as procurement sensitive, proprietary, or with appropriate Government markings.
b) Sensitive, proprietary, and Government documents should be maintained in a lockable filing cabinet/desk or other storage device and not be left unattended.
c) Access to sensitive information should be restricted to those with a need to know.

B. Document Destruction

a) Documents must be destroyed using approved destruction measures (i.e., shredders/approved third party vendors / pulverizing / incinerating).

8. Information Technology and Cybersecurity

A. Identity Management

a) Physical devices and systems within the organization are inventoried and accounted for annually.
b) Organizational cybersecurity policy is established and communicated.
c) Asset vulnerabilities are identified and documented.
d) Cyber threat intelligence is received from information sharing forums and sources.
e) Threats, vulnerabilities, likelihoods, and impacts are used to determine risk.
f) Identities and credentials are issued, managed, verified, revoked, and audited for authorized devices, users and processes.
g) Users, devices, and other assets are authenticated (e.g., single-factor, multifactor) commensurate with the risk of the transaction (e.g., individuals security and privacy risks and other organizational risks).

B. Access Control

a) Limit information system access to authorized users.
b) Identify information system users, processes acting on behalf of users, or devices and authenticate identities before allowing access.
c) Limit physical access to information systems, equipment, and server rooms with electronic access controls.
d) Limit access to/verify access to use of external information systems.

C. Training

a) Ensure that personnel are trained and are made aware of the security risks associated with their activities and of the applicable laws, policies, standards, regulations, or procedures related to information technology systems.

D. Audit and Accountability

a) Create, protect, and retain information system audit records to the extent needed to enable the monitoring, analysis, investigation, and reporting of unlawful, unauthorized, or inappropriate system activity. Records must be kept for minimum of [REDACTED].
b) Ensure the actions of individual information system users can be uniquely traced to those users.
c) Update malicious code mechanisms when new releases are available.
d) Perform periodic scans of the information system and real-time scans of files from external sources as files are downloaded, opened, or executed.

E. Configuration Management
a) Establish and enforce security configuration settings.
b) Implement sub networks for publically accessible system components that are physically or logically separated from internal networks.

F. Contingency Planning
a) Establish, implement, and maintain plans for emergency response, backup operations, and post-disaster recovery for information systems to ensure the availability of critical information resources at all times.

G. Incident Response
a) Establish an operational incident handling capability for information systems that includes adequate preparation, detection, analysis, containment, and recovery of cybersecurity incidents. Exercise this capability annually.

H. Media and Information Protection
a) Protect information system media, both paper and digital.
b) Limit access to information on information systems media to authorized users.
c) Sanitize and destroy media no longer in use.
d) Control the use of removable media through technology or policy.

I. Physical and Environmental Protection
a) Limit access to information systems, equipment, and the respective operating environments to authorized individuals.
b) Intrusion detection and prevention system employed on IT networks.
c) Protect the physical and support infrastructure for all information systems.
d) Protect information systems against environmental hazards.
e) Escort visitors and monitor visitor activity.

J. Network Protection
a) Employ intrusion prevention and detection technology with immediate analysis capabilities.

K. Transportation Security
Description: Adequate security controls must be implemented to protect materials while in transit from theft, destruction, manipulation, or damage.

A. Drivers
a) Drivers must be vetted in accordance with Government Personnel Security Requirements.
b) Drivers must be trained on specific security and emergency procedures.
c) Drivers must be equipped with backup communications.
d) Driver identity must be 100 percent confirmed before the pick-up of any Government product.
e) Drivers must never leave Government products unattended, and two drivers may be required for longer transport routes or critical products during times of emergency.
f) Truck pickup and deliveries must be logged and kept on record for a minimum of [60 days].

B. Transport Routes
a) Transport routes should be pre-planned and never deviated from except when approved or in the event of an emergency.
b) Transport routes should be continuously evaluated based upon new threats, significant planned events, weather, and other situations that may delay or disrupt transport.

C. Product Security
a) Government products must be secured with tamper resistant seals during transport, and the transport trailer must be locked and sealed.
   - Tamper resistant seals must be verified as secure after the product is placed in the transport vehicle.
b) Government products should be continually monitored by GPS technology while in transport, and any deviations from planned routes should be investigated and documented.

10. Security Reporting Requirements

Description: The partner facility shall notify the Government Security Team within [48 hours] of any activity or incident that is in violation of established security standards or indicates the loss or theft of Government products. The facts and circumstances associated with these incidents will be documented in writing for Government review.

11. Security Audits

Description: The partner facility agrees to formal security audits conducted at the discretion of the Government. Security audits may include both prime and subcontractor.

*** END OF NARRATIVE F0001 ***
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

### CONTRACT ADMINISTRATION DATA

<table>
<thead>
<tr>
<th>ITEM</th>
<th>GEARS STA</th>
<th>STAT</th>
<th>ACCT ASSIGN</th>
<th>ACRN</th>
<th>OBLIGATED AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0081AA</td>
<td>CB1RD13635</td>
<td>2</td>
<td>S.0074658.5.40</td>
<td>AA</td>
<td>$ (0) (4)</td>
</tr>
<tr>
<td>0081AB</td>
<td>CB1RD14381</td>
<td>2</td>
<td>S.0074658.5.40.1</td>
<td>AB</td>
<td>$ (0) (4)</td>
</tr>
<tr>
<td>0081AC</td>
<td>CB1RD41544</td>
<td>2</td>
<td>S.0074658.5.40.2</td>
<td>AC</td>
<td>$ (0) (4)</td>
</tr>
</tbody>
</table>

**TOTAL** $ 2,625,000,000.00

<table>
<thead>
<tr>
<th>ACRN</th>
<th>ACCOUNTING CLASSIFICATION</th>
<th>OBLIGATED AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>021 2021200220040 A5XAH 654807849FL8D 255Y L071413635 S.0074658.5.40 021001</td>
<td>$ (0) (4)</td>
</tr>
<tr>
<td>AB</td>
<td>021 2021200220040 A5XAH 654807849FL8D 255Y L071414381 S.0074658.5.40.1 021001</td>
<td>$ (0) (4)</td>
</tr>
<tr>
<td>AC</td>
<td>021 2021200220040 A5XAH 654807849FL8D 255Y L071414544 S.0074658.5.40.2 021001</td>
<td>$ (0) (4)</td>
</tr>
</tbody>
</table>

**TOTAL** $ 2,625,000,000.00

### Regulatory Cite

<table>
<thead>
<tr>
<th>Regulatory Cite</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>252.232-7006</td>
<td>WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS</td>
<td>DEC/2018</td>
</tr>
</tbody>
</table>

(a) Definitions. As used in this clause--

*Department of Defense Activity Address Code (DoDAAC)* is a six position code that uniquely identifies a unit, activity, or organization.

*Document type* means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).

*Local Processing Office (LPO)* is the office responsible for payment certification when payment certification is done external to the entitlement system.

*Payment request* and *receiving report* are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.

(b) Electronic invoicing. The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.

(c) WAWF access. To access WAWF, the Contractor shall--

1. Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov ; and


(d) WAWF training. The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the "Web Based Training" link on the WAWF home page at https://wawf.eb.mil/ .
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

(e) WAWF methods of document submission. Document submissions may be via Web entry, Electronic Data Interchange, or File Transfer Protocol.

(f) WAWF payment instructions. The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:

(1) Document type. The Contractor shall submit payment requests using the following document type(s):

(i) For cost-type line items, including labor-hour or time-and-materials, submit a cost voucher.

(ii) For fixed price line items—

(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.

Invoice (Contractor Only)

(B) For services that do not require shipment of a deliverable, submit either the Invoice 2-in-1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.

Invoice as 2-in-1

(iii) For customary progress payments based on costs incurred, submit a progress payment request.

(iv) For performance based payments, submit a performance based payment request.

(v) For commercial item financing, submit a commercial item financing request.

(2) Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.

[Note: The Contractor may use a WAWF "combo" document type to create some combinations of invoice and receiving report in one step.]

(3) Document routing. The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.

Routing Data Table

<table>
<thead>
<tr>
<th>Field Name in WAWF</th>
<th>Data to be entered in WAWF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pay Official DoDAAC</td>
<td>HQ0490</td>
</tr>
<tr>
<td>Issue By DoDAAC</td>
<td>W15QKN</td>
</tr>
<tr>
<td>Admin DoDAAC</td>
<td>W15QKN</td>
</tr>
<tr>
<td>Inspect By DoDAAC</td>
<td>TBD</td>
</tr>
<tr>
<td>Ship To Code</td>
<td>TBD</td>
</tr>
<tr>
<td>Ship From Code</td>
<td>TBD</td>
</tr>
<tr>
<td>Mark For Code</td>
<td>TBD</td>
</tr>
<tr>
<td>Service Approver (DoDAAC)</td>
<td>N/A</td>
</tr>
<tr>
<td>Service Acceptor (DoDAAC)</td>
<td>N/A</td>
</tr>
<tr>
<td>Accept at Other DoDAAC</td>
<td>N/A</td>
</tr>
<tr>
<td>LEO DoDAAC</td>
<td>N/A</td>
</tr>
<tr>
<td>DCAA Auditor DoDAAC</td>
<td>N/A</td>
</tr>
<tr>
<td>Other DoDAAC(s)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(4) Payment request. The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.

(5) Receiving report. The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.

(g) WAWF point of contact.

(1) The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact.
(2) Contact the WAWF helpdesk at 866-618-5908, if assistance is needed.

(End of clause)
SPECIAL CONTRACT REQUIREMENTS

As this is a commercial contract, any special requirements contained in this section and throughout the contract, are incorporated by addendum.

1. OWS REQUIRED CLAUSE

   1. Key Personnel

   Any key personnel specified in this contract are considered to be essential to work performance. At least prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts, the Contractor shall notify the CO and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement’s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than , the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the CO. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel:

   Reference Regeneron’s Technical Proposal dated 29 December 2020, Section 2.3.1.1, Program Management, for a listing of key personnel

II. Substitution of Key Personnel

The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made, except in accordance with this clause.

   All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the CO to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The CO or authorized representative (TPOC) will evaluate such requests and promptly notify the Contractor of his approval or disapproval thereof.

The Contractor further agrees to include the substance of this clause in any subcontract, which may be awarded under this contract.

III. Disclosure of Information

Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor, or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data or information obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO in accordance with OWS or other Government policies and/or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.

The Contractor shall comply with all Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractors employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, a breach of the activity’s security or interrupt the continuity of its operations.

No information related to data obtained from the Government under this contract shall be released or publicized without the prior written consent of the TPOC, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any Government entity for submission to any securities exchange on which the Contractors (or its parent corporations) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.

IV. Publications and Publicity

The Contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.

   (a) Unless otherwise specified in this contract, the Contractor may publish the results of its work under this contract. The Contractor shall promptly send a copy of each submission to the TPOC for security review prior to submission. The Contractor shall also inform the TPOC when the abstract article or other publication is published, and furnish a copy of it as finally published.
(b) Unless authorized in writing by the CO, the Contractor shall not display Government logos, including Operating Division or Staff Division logos on any publications.

(c) The Contractor shall not reference the product(s) or service(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies Government approval or endorsement of the product(s) or service(s) provided.

(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The Contractor shall acknowledge the support of the Government whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:

"This project has been funded in whole or in part by the U.S. Government under Contract No. W15QKN-21-C-0014. The US Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon."

V. Confidentiality of Information

a. Confidential information, as used in this article, means information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.

b. The CO and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the CO and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the "Disputes" clause.

c. If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.

d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.

e. Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the CO prior to any release, disclosure, dissemination, or publication.

f. Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.

g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.

All above requirements MUST be passed to all sub-contractors.

VI. Organizational Conflicts of Interest

Performance under this contract may create an actual or potential organizational conflict of interest such as are contemplated by FAR Part 9.505-General Rules. The Contractor shall not engage in any other contractual or other activities which could create an Organizational Conflict of Interest (OCI). This provision shall apply to the prime Contractor and all sub-contractors. This provision shall have effect throughout the period of performance of this contract, any extensions thereof by change order or supplemental agreement, and for two (2) years thereafter. The Government may pursue such remedies as may be permitted by law or this contract, upon determination that an OCI has occurred.

The work performed under this contract may create a significant potential for certain conflicts of interest, as set forth in FAR Parts 9.505-1, 9.505-2, 9.505-3, and 9.505-4. It is the intention of the parties hereto to prevent both the potential for bias in connection with the Contractors performance of this contract, as well as the creation of any unfair competitive advantage as a result of knowledge gained through access to any non-public data or third party proprietary information.

The Contractor shall notify the CO immediately whenever it becomes aware that such access or participation may result in any actual or potential OCI. Furthermore, the Contractor shall promptly submit a plan to the CO to either avoid or mitigate any such OCI. The CO will have sole discretion in accepting the Contractors mitigation plan. In the event the CO unilaterally determines that any such OCI cannot be satisfactorily avoided or mitigated, other remedies may be taken to prohibit the Contractor from participating in contract requirements related to OCI.

Whenever performance of this contract provides access to another Contractors proprietary information, the Contractor shall enter into a written agreement with the other entities involved, as appropriate, in order to protect such proprietary information from unauthorized use or disclosure for as long as it remains proprietary; and refrain from using such proprietary information other than as agreed to,
2. HEALTH RESOURCE PRIORITY AND ALLOCATIONS SYSTEM (HRPAS)

In order to ensure the success of Regeneron’s efforts, a priority rating is incorporated into the contract for the procurement of raw materials, consumables, repair parts, and major end item assemblies by Regeneron under Title I of the HRPAS.

Priority Rating: Defense Production Act (DPA) Title I DO-HR

Each rated order executed by Regeneron must include the following:

(a) The priority rating: DPA Title I DO-HR;

(b) A required delivery date or dates. The words immediately or as soon as possible do not constitute a delivery date;

(c) The written signature on a manually placed order, or the digital signature or name on an electronically placed order, of an individual authorized to sign rated orders for the person placing the order; and

(d) A statement that reads in substance:

(i) This is a rated order certified for national defense use, and you are required to follow all the provisions of the Health Resources Priorities and Allocations System regulation at 45 CFR part 101.

(ii) If the rated order is placed in support of emergency preparedness requirements and expedited action is necessary and appropriate to meet these requirements, the following sentences should be added following the statement set forth in paragraph (d)(1) of this section:

A. The order is issued in response to a hazard that has occurred; or

B. If the order is issued to prepare for an imminent hazard, as specified in HRPAS Section 101.33(e).

3. ENSURING SUFFICIENT SUPPLY OF THE PRODUCT

1. In recognition of the Government’s need to provide sufficient quantities of a COVID-19 therapeutic to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions ((a) and (b)) are met:

(a) Regeneron gives written notice, required to be submitted to the Government no later than [DATE], of:

i. any formal management decision to terminate manufacturing of this product therapeutic prior to delivery of the minimum required doses to the U.S. Government under this contract, as well as all additional orders accepted by the Contractor, other than as a result of clinical failure, or serious technical or safety reasons;

or;

ii. any formal management decision to discontinue sale of this product therapeutic to the Government prior to delivery of the minimum required doses to the U.S. Government under this contract, as well as all additional orders accepted by the Contractor, other than as a result of clinical failure, or serious technical or safety reasons; or any filing that anticipates Federal bankruptcy protection; and

(b) Regeneron has submitted an Emergency Use Authorization application under Section 564 of the Food, Drug, and Cosmetic (FD&C) Act or a biologics license application under the provisions of Section 351(a) of the Public Health Service Act (PHSA).

2. If both conditions listed in section 1 occur, Regeneron, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of this therapeutic product with a third party for exclusive sale to the U.S. Government:
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

(a) a writing, evidencing a non-exclusive, non-transferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for on behalf of the U.S. Government, any Regeneron Background Patent, Copyright, other Regeneron Intellectual Property, Regeneron Know-How, and Regeneron Technical Data rights necessary to manufacture doses of the SARSCoV2 medical countermeasure neutralizing monoclonal antibodies, designated as casirivimab and imdevimab; necessary FDA regulatory filings or authorizations owned or controlled by Regeneron related to this therapeutic product, and any confirmatory instrument pertaining thereto; and

(b) any outstanding Deliverables contemplated or materials purchased under this contract.

3. This remedy will remain available until the end of the contract, and the license rights and items may only be used by the Government and its contractors to the extent needed to manufacture the number of doses that are not received under this contract, including with respect to any additional orders that are accepted by the Contractor.

*** END OF NARRATIVE H0001 ***
**CONTRACT CLAUSES**

<table>
<thead>
<tr>
<th>Regulatory Cite</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>52.204-13</td>
<td>SYSTEM FOR AWARD MANAGEMENT MAINTENANCE</td>
<td>OCT/2018</td>
</tr>
<tr>
<td>52.204-18</td>
<td>COMMERCIAL AND GOVERNMENT ENTITY CODE MAINTENANCE</td>
<td>AUG/2020</td>
</tr>
<tr>
<td>52.212-4</td>
<td>CONTRACT TERMS AND CONDITIONS--COMMERCIAL ITEMS</td>
<td>OCT/2018</td>
</tr>
<tr>
<td>52.219-16</td>
<td>LIQUIDATED DAMAGES--SUBCONTRACTING PLAN</td>
<td>JAN/1999</td>
</tr>
<tr>
<td>52.232-40</td>
<td>PROVIDING ACCELERATED PAYMENTS TO SMALL BUSINESS SUBCONTRACTORS</td>
<td>DEC/2013</td>
</tr>
<tr>
<td>252.203-7000</td>
<td>REQUIREMENTS RELATING TO COMPENSATION OF FORMER DOD OFFICIALS</td>
<td>SEP/2011</td>
</tr>
<tr>
<td>252.203-7002</td>
<td>REQUIREMENT TO INFORM EMPLOYEES OF WHISTLEBLOWER RIGHTS</td>
<td>SEP/2013</td>
</tr>
<tr>
<td>252.203-7003</td>
<td>AGENCY OFFICE OF THE INSPECTOR GENERAL</td>
<td>AUG/2019</td>
</tr>
<tr>
<td>252.204-7003</td>
<td>CONTROL OF GOVERNMENT PERSONNEL WORK PRODUCT</td>
<td>APR/1992</td>
</tr>
<tr>
<td>252.204-7012</td>
<td>SAFEGUARDING COVERED DEFENSE INFORMATION AND CYBER INCIDENT REPORTING</td>
<td>DEC/2019</td>
</tr>
<tr>
<td>252.204-7015</td>
<td>NOTICE OF AUTHORIZED DISCLOSURE OF INFORMATION FOR LITIGATION SUPPORT</td>
<td>MAY/2016</td>
</tr>
<tr>
<td>252.204-7020</td>
<td>NIST SP 800-171 DOD ASSESSMENT REQUIREMENTS</td>
<td>MAR/2019</td>
</tr>
<tr>
<td>252.205-7009</td>
<td>PROVISION OF INFORMATION TO COOPERATIVE AGREEMENT HOLDERS</td>
<td>DEC/1993</td>
</tr>
<tr>
<td>252.209-7004</td>
<td>SUBCONTRACTING WITH FIRMS THAT ARE OWNED OR CONTROLLED BY THE GOVERNMENT OF A TERRORIST COUNTRY</td>
<td>MAY/2019</td>
</tr>
<tr>
<td>252.219-7003</td>
<td>SMALL BUSINESS SUBCONTRACTING PLAN (DOD CONTRACTS)--BASIC</td>
<td>DEC/2019</td>
</tr>
<tr>
<td>252.225-7012</td>
<td>PREFERENCE FOR CERTAIN DOMESTIC COMMODITIES</td>
<td>DEC/2017</td>
</tr>
<tr>
<td>252.227-7015</td>
<td>TECHNICAL DATA--COMMERCIAL ITEMS</td>
<td>FEB/2014</td>
</tr>
<tr>
<td>252.232-7003</td>
<td>ELECTRONIC SUBMISSION OF PAYMENT REQUESTS AND RECEIVING REPORTS</td>
<td>DEC/2018</td>
</tr>
<tr>
<td>252.232-7010</td>
<td>LEVIES ON CONTRACT PAYMENTS</td>
<td>DEC/2006</td>
</tr>
<tr>
<td>252.232-7017</td>
<td>ACCELERATING PAYMENTS TO SMALL BUSINESS SUBCONTRACTORS--PROHIBITION ON FEES AND CONSIDERATION</td>
<td>APR/2020</td>
</tr>
<tr>
<td>252.243-7002</td>
<td>REQUESTS FOR EQUITABLE ADJUSTMENT</td>
<td>DEC/2012</td>
</tr>
<tr>
<td>252.244-7000</td>
<td>SUBCONTRACTS FOR COMMERCIAL ITEMS</td>
<td>OCT/2020</td>
</tr>
<tr>
<td>252.247-7023</td>
<td>TRANSPORTATION OF SUPPLIES BY SEA--BASIC</td>
<td>FEB/2019</td>
</tr>
<tr>
<td>52.212-5</td>
<td>CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT STATUTES OR EXECUTIVE ORDERS--COMMERCIAL ITEMS</td>
<td>NOV/2020</td>
</tr>
</tbody>
</table>

(a) The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract by reference, to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

1. 52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (JAN 2017) (section 703 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).

2. 52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (JUL 2018) (Section 1636 of Pub. L. 115-91).

3. 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (AUG 2020) (Section 889(a)(1)(A) of Pub. L. 115-232).

4. 52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (NOV 2015)


(b) The Contractor shall comply with the FAR clauses in this paragraph (b) that the contracting officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items:


Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

(5) [Reserved].


(10) [Reserved]

(i) 52.219–3, Notice of HUBZone Set-Aside or Sole-Source Award (MAR 2020) (15 U.S.C. 657a).

(ii) Alternate I (MAR 2020) of 52.219–3.

(iii) Alternate II (Nov 2011) of 52.219–3.

(iv) Alternate III (Nov 2020) of 52.219–3.

(v) Alternate IV (Jun 2020) of 52.219–3.

(12) (i) 52.219–4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (MAR 2020) (if the offeror elects to waive the preference, it shall so indicate in its offer) (15 U.S.C. 657a).

(ii) Alternate I (MAR 2020) of 52.219–4.

(iii) Alternate II (MAR 2020) of 52.219–4.

(13) [Reserved]


(ii) Alternate I (MAR 2020) of 52.219–6.

(iii) Alternate II (Nov 2011) of 52.219–6.

(iv) Alternate III (Nov 2020) of 52.219–6.


(ii) Alternate I (MAR 2020) of 52.219–7.

(iii) Alternate II (Mar 2004) of 52.219–7.


(16) 52.219–8, Utilization of Small Business Concerns (Oct 2018) (15 U.S.C. 637(d)(2) and (3)).

(17) (i) 52.219–9, Small Business Subcontracting Plan (Jun 2020) (15 U.S.C. 637(d)(4)).

(ii) Alternate I (Nov 2016) of 52.219–9.

(iii) Alternate II (Nov 2016) of 52.219–9.

(iv) Alternate III (Jun 2020) of 52.219–9.

(v) Alternate IV (Jun 2020) of 52.219–9.

(18) (i) 52.219–13, Notice of Set-Aside of Orders (MAR 2020) (15 U.S.C. 644(r)).


(19) 52.219–14, Limitations on Subcontracting (MAR 2020) (15 U.S.C. 637(a)(14)).


(22) (i) 52.219–28, Post Award Small Business Program Reapportionment (Nov 2020) (15 U.S.C. 632(a)(2)).

(ii) Alternate I (MAR 2020) of 52.219–28.

(23) 52.219–29 Notice of Total Set-Aside for Economically Disadvantaged Woman-Owned Small Business (EDWOSB) Concerns (MAR 2020)
<table>
<thead>
<tr>
<th>Reference No. of Document Being Continued</th>
<th>Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIN/SIN</td>
<td>MOD/AMD</td>
</tr>
</tbody>
</table>

(15 U.S.C. 637(m)).

<p>| (24) | 52.219-30 Notice of Total Set-Aside for Women-Owned Small Business (WOSB) Concerns Eligible Under the WOSB Program (MAR 2020) (15 U.S.C. 644(r)). |
| (26) | 52.219-33, Nonmanufacturer Rule (MAR 2020) (15 U.S.C. 637(e)(17)). |
| (27) | 52.222-3, Convict Labor (June 2003) (E.O. 11755). |
| (28) | 52.222-19, Child Labor Cooperation with Authorities and Remedies (Jan 2020) (E.O. 13126). |
| (29) | 52.222-21, Prohibition of Segregated Facilities (Apr 2015). |
| (30) | 52.222-26, Equal Opportunity (Sep 2016) (E.O. 11246). |
| (34) | 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) (E.O. 13496). |
| (36) | 52.222-54, Employment Eligibility Verification (Oct 2015) (Executive Order 12989). (Not applicable to the acquisition of commercially available off-the-shelf items or certain other types of commercial items as prescribed in 22.1803.) |
| (37) | 52.223-9, Estimate of Percentage of Recovered Material Content for EPA-Designated Items (May 2008) (42 U.S.C. 6962(c)(3)(A)(I)(I)). (Not applicable to the acquisition of commercially available off-the-shelf items.) |
| (38) | 52.223-11, Ozone-Depleting Substances and High Global Warming Potential Hydrofluorocarbons (June, 2016) (E.O. 13693). |
| (39) | 52.223-12, Maintenance, Service, Repair, or Disposal of Refrigeration Equipment and Air Conditioners (June, 2016) (E.O. 13693). |
| (40) | 52.223-13, Acquisition of EPEAT-supplereg-Registered Imaging Equipment (Jun 2014) (E.O.s 13423 and 13514). |
| (41) | 52.223-14, Acquisition of EPEAT-supplereg-Registered Televisions (Jun 2014) (E.O.s 13423 and 13514). |
| (43) | 52.223-16, Acquisition of EPEAT-supplereg-Registered Personal Computer Products (Oct 2015) (E.O.s 13423 and 13514). |
| (44) | 52.223-18, Encouraging Contractor Policies to Ban Text Messaging While Driving (Jun 2020) (E.O. 13513). |</p>
<table>
<thead>
<tr>
<th>Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(45) 52.223-20, Aerosols (June, 2016) (E.O. 13693).</td>
</tr>
<tr>
<td>(46) 52.223-21, Foams (June, 2016) (E.O. 13693).</td>
</tr>
<tr>
<td>(ii) Alternate I (JAN 2017) of 52.224-3.</td>
</tr>
<tr>
<td>(ii) Alternate I (MAY 2014) of 52.225-3.</td>
</tr>
<tr>
<td>(iii) Alternate II (MAY 2014) of 52.225-3.</td>
</tr>
<tr>
<td>(iv) Alternate III (MAY 2014) of 52.225-3.</td>
</tr>
<tr>
<td>(51) 52.225-13, Restrictions on Certain Foreign Purchases (Jun 2008) (E.O.s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury).</td>
</tr>
<tr>
<td>(53) 52.226-4, Notice of Disaster or Emergency Area Set-Aside (Nov 2007) (42 U.S.C. 5150).</td>
</tr>
<tr>
<td>(54) 52.226-5, Restrictions on Subcontracting Outside Disaster or Emergency Area (Nov 2007)(42 U.S.C. 5150).</td>
</tr>
<tr>
<td>(55) 52.229-12, Tax on Certain Foreign Procurements (JUN 2020).</td>
</tr>
<tr>
<td>(56) 52.232-29, Terms for Financing of Purchases of Commercial Items (Feb 2002)(41 U.S.C. 4505, 10 U.S.C. 2307(f)).</td>
</tr>
<tr>
<td>(57) 52.232-30, Installment Payments for Commercial Items (Jan 2017)(41 U.S.C. 4505, 10 U.S.C. 2307(f)).</td>
</tr>
<tr>
<td>(59) 52.232-34, Payment by Electronic Funds Transfer -- Other Than System for Award Management (Jul 2013)(31 U.S.C. 3332).</td>
</tr>
<tr>
<td>(62) 52.242-5, Payments to Small Business Subcontractors (Jan 2017)(15 U.S.C. 637(d)(13)).</td>
</tr>
<tr>
<td>(63)(i) 52.247-64, Preference for Privately Owned U.S.-Flag Commercial Vessels (Feb 2006)(46 U.S.C. Appx 1241(b) and 19 U.S.C. 2631).</td>
</tr>
<tr>
<td>(ii) Alternate I (Apr 2003) of 52.247-64.</td>
</tr>
<tr>
<td>(iii) Alternate II (Feb 2006) of 52.247-64.</td>
</tr>
</tbody>
</table>

(c) The Contractor shall comply with the FAR clauses in this paragraph (c), applicable to commercial services, that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or executive orders applicable to acquisitions of commercial items:

Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.


__ (9) 52.226-6, Promoting Excess Food Donation to Nonprofit Organizations (Jun 2020) (42 U.S.C. 1792).

(d) Controller General Examination of Record. The Contractor shall comply with the provisions of this paragraph (d) if this contract was awarded using other than sealed bid, is in excess of the simplified acquisition threshold, as defined in FAR 2.101, on the date of award of this contract, and does not contain the clause at 52.215-2, Audit and Records -- Negotiation.

(1) The Controller General of the United States, or an authorized representative of the Controller General, shall have access to and right to examine any of the Contractor's directly pertinent records involving transactions related to this contract.

(2) The Contractor shall make available at its offices at all reasonable times the records, materials, and other evidence for examination, audit, or reproduction, until 3 years after final payment under this contract or for any shorter period specified in FAR Subpart 4.7, Contractor Records Retention, of the other clauses of this contract. If this contract is completely or partially terminated, the records relating to the work terminated shall be made available for 3 years after any resulting final termination settlement. Records relating to appeals under the disputes clause or to litigation or the settlement of claims arising under or relating to this contract shall be made available until such appeals, litigation, or claims are finally resolved.

(3) As used in this clause, records include books, documents, accounting procedures and practices, and other data, regardless of type and regardless of form. This does not require the Contractor to create or maintain any record that the Contractor does not maintain in the ordinary course of business or pursuant to a provision of law.

(e)(1) Notwithstanding the requirements of the clauses in paragraphs (a), (b), (c) and (d) of this clause, the Contractor is not required to flow down any FAR clause, other than those in this paragraph (e)(1) in a subcontract for commercial items. Unless otherwise indicated below, the extent of the flow down shall be as required by the clause--


(ii) 52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (JAN 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).

(iii) 52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (Jul 2018) (Section 1834 of Pub. L. 115-91).

(iv) 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (AUG 2020) (Section 889(a)(1)(H) of Pub. L. 115-232).

(v) 52.219-8, Utilization of Small Business Concerns (Oct 2018) (15 U.S.C. 637(d)(2) and (3)), in all subcontracts that offer further subcontracting opportunities. If the subcontract (except subcontracts to small business concerns) exceeds the applicable threshold specified in FAR 19.702(a) on the date of subcontract award, the subcontractor must include 52.219-8 in lower tier subcontracts that offer subcontracting opportunities.

(vi) 52.222-21, Prohibition of Segregated Facilities (Apr 2015).

(vii) 52.222-26, Equal Opportunity (Sep 2016) (E.O. 11246).


(xi) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (DEC 2010) (E.O. 13496).

(xiii) (A) 52.222-50, Combating Trafficking in Persons (Oct 2020) {22 U.S.C. 7104(g)}.

(B) Alternate I (Mar 2015) of 52.222-50 {22 U.S.C. 7104(g)}.

(xiv) 52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment--Requirements (MAY 2014) {41 U.S.C. chapter 67}.


(xvi) 52.222-54, Employment Eligibility Verification (Oct 2015).

(xvii) 52.222-55, Minimum Wages Under Executive Order 13658 (Nov 2020) {Executive Order 13658}.

(xviii) 52.222-62 Paid Sick Leave Under Executive Order 13706 (Jan 2017) {E.O. 13706}.

(xix) (A) 52.224-3, Privacy Training (JAN 2017) {5 U.S.C. 552a}.

(B) Alternate I (JAN 2017) of 52.224-3.


(xx) 52.228-6, Promoting Excess Food Donation to Nonprofit Organizations (Jun 2020) {42 U.S.C. 1792}. Flow down required in accordance with paragraph (e) of FAR clause 52.228-6.

(xxii) 52.247-64, Preference for Privately-Owned U.S. Flag Commercial Vessels (Feb 2006) {46 U.S.C. Appx 1241(b) and 10 U.S.C. 2631}. Flow down required in accordance with paragraph (d) of FAR clause 52.247-64.

(2) While not required, the Contractor may include in its subcontracts for commercial items a minimal number of additional clauses necessary to satisfy its contractual obligations.
Name of Offeror or Contractor: REGENERON PHARMACEUTICALS, INC.

<table>
<thead>
<tr>
<th>List of Attachments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addenda</td>
</tr>
<tr>
<td>Exhibit A</td>
</tr>
<tr>
<td>Attachment 0001</td>
</tr>
<tr>
<td>Attachment 0002</td>
</tr>
</tbody>
</table>
W15QKN-21-C-
Exhibit A
Contract Data Requirements List
CDRLs

Date: 07 January 2021
# of pages: 32
The Awardee shall complete an initial teleconference after agreement award:

1. Outline activities for the next [b](4)
2. Discuss agenda items for the post-award Kickoff Meeting (A002)

Within one week of Agreement award:

- Awardee shall provide agenda and establish a teleconference number at least [b](4) in advance of the teleconference unless notified that BARDA will supply one.
- AOR edits/approves and instructs Awardee to distribute agenda prior to meeting by at least [b](4).
- Awardee provides meeting minutes to AOR within [b](4) after the meeting.
- AOR reviews, comments, and approves minutes within [b](4).

<table>
<thead>
<tr>
<th>REMARKS</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Awardee shall complete an initial teleconference after agreement award.</td>
</tr>
<tr>
<td>1. Outline activities for the next <a href="4">b</a></td>
</tr>
<tr>
<td>2. Discuss agenda items for the post-award Kickoff Meeting (A002)</td>
</tr>
<tr>
<td>Within one week of Agreement award:</td>
</tr>
<tr>
<td>• Awardee shall provide agenda and establish a teleconference number at least <a href="4">b</a> in advance of the teleconference unless notified that BARDA will supply one.</td>
</tr>
<tr>
<td>• AOR edits/approves and instructs Awardee to distribute agenda prior to meeting by at least <a href="4">b</a>.</td>
</tr>
<tr>
<td>• Awardee provides meeting minutes to AOR within <a href="4">b</a> after the meeting.</td>
</tr>
<tr>
<td>• AOR reviews, comments, and approves minutes within <a href="4">b</a>.</td>
</tr>
</tbody>
</table>

| TOTAL | 2 0 0 |

<table>
<thead>
<tr>
<th>DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
</tr>
<tr>
<td>JPEO CBRND</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
</tr>
<tr>
<td>JPEO CBRND</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRICE GROUP</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ESTIMATED TOTAL PRICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

## DD FORM 1423-1, FEB 2001
PREVIOUS EDITION MAY BE USED.
The Awardee shall complete a Kickoff meeting after agreement award. Within 45 days of agreement award, pending concurrence by the agreements officer:

- Awardee shall provide itinerary and agenda at least 48 hours in advance of site visit or virtual meeting.
- AOR edits/approves and instructs Awardee to distribute agenda prior to meeting by at least 48 hours before the meeting.
- Awardee provides meeting minutes to AOR within 48 hours after the meeting.
- AOR reviews, comments, and approves minutes within 48 hours after receipt.
### CONTRACT DATA REQUIREMENTS LIST

**Form Approved**  
OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Respondents are invited to suggest ways to improve the quality of the OMB control number. Send comments to the Department of Defense, Executive Office of the President/Office of Information and Regulatory Affairs, Attention: OMB/OMB Paper Clearance Office, New Executive Office Building, Washington, DC 20503-0001. Do not send the form to this address. Please return the completed form to the Government Issuing Contracting Officer for the contract/PR No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>0001</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. EXHIBIT</td>
<td>A</td>
</tr>
<tr>
<td>C. CATEGORY:</td>
<td>TDF X</td>
</tr>
<tr>
<td>D. SYSTEM ITEM</td>
<td>Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Teleconference Minutes</td>
</tr>
<tr>
<td>E. CONTRACT/PR NO.</td>
<td>W15QKN21C</td>
</tr>
<tr>
<td>F. CONTRACTOR</td>
<td>Regeneron</td>
</tr>
<tr>
<td>G. DATA ITEM NO.</td>
<td>A003</td>
</tr>
<tr>
<td>H. TITLE OF DATA ITEM</td>
<td>Teleconference Minutes</td>
</tr>
<tr>
<td>I. SUBSTITUTE</td>
<td></td>
</tr>
<tr>
<td>J. AUTHORITY</td>
<td>DI-ADMN-81505</td>
</tr>
<tr>
<td>K. CONTRACT REFERENCE</td>
<td>SOW</td>
</tr>
<tr>
<td>L. REQUIRING OFFICE</td>
<td>BARDA</td>
</tr>
<tr>
<td>M. AGENDA</td>
<td></td>
</tr>
<tr>
<td>N. AS OF DATE</td>
<td></td>
</tr>
<tr>
<td>O. DATE OF SUBSEQUENT SUBMISSION</td>
<td></td>
</tr>
<tr>
<td>P. FREQUENCY</td>
<td></td>
</tr>
<tr>
<td>Q. DISTRIBUTION</td>
<td></td>
</tr>
<tr>
<td>R. ADDRESS</td>
<td></td>
</tr>
<tr>
<td>S. DATES</td>
<td></td>
</tr>
<tr>
<td>T. REMARKS</td>
<td>The awardee shall participate in teleconferences every (b) (4) with BARDA to discuss the performance on the Agreement. Meeting frequency can be increased with agreement between both parties as needed during the course of the project. Awardee provides agenda to AOR no later than (b) (4) in advance of meeting. AOR edits/approves and instructs Awardee to distribute agenda prior to meeting. Awardee distributes agenda and presentation materials if needed at least (b) (4) in advance. Awardee provides meeting minutes to AOR within (b) (4) of the meeting. AOR reviews, comments, and approves minutes within (b) (4). Updates to include distribution and regulatory issues.</td>
</tr>
<tr>
<td>U. TOTAL</td>
<td>2 0 0</td>
</tr>
</tbody>
</table>

DD FORM 1423-1, FEB 2001  
PREVIOUS EDITION MAY BE USED.
The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directories, OMB No. 0704-0188. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Office for the Contract No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>TID  X IM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM/ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>W15QKNZ1C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A. DATA ITEM NO.</th>
<th>B. TITLE OF DATA ITEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>A004</td>
<td>Quarterly Meetings</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. AUTHORITY (Data Acquistion Document No.)</th>
<th>D. SYSTEM/ITEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>DL-ADMIN-81505</td>
<td>Therapeutics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>W15QKNZ1C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. PREPARED BY</th>
<th>H. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (6)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I. APPROVED BY</th>
<th>J. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (6)</td>
<td></td>
</tr>
</tbody>
</table>

At the discretion of the government the Awardee shall hold recurring teleconference or face-to-face Project Review Meetings up to four per year either in Washington D.C. or at work sites of the Awardee or sub-awardees. Face-to-face meetings shall alternate between Washington DC and Awardee, sub-awardee sites. The meetings will be used to discuss agreement progress in relation to the Program Management deliverables described below as well as technical, and regulatory aspects of the program.

- Awardee shall provide itinerary and agenda at least (b) (4) days in advance of site visit
- Awardee shall provide meeting minutes to AOR within (b) (4) days after the meeting
- AOR reviews comments and approves minutes within (b) (4) days

<table>
<thead>
<tr>
<th>17. PRICE GROUP</th>
<th>18. ESTIMATED TOTAL PRICE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DD FORM 1423-1, FEB 2001
**CONTRACT DATA REQUIREMENTS LIST**

(1 Data Item)

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and submitting the collection of information. Respondents are advised that under the law, only responses to this collection of information may be subject to the confidentiality of information if it does not display a currently valid OMB control number. Respondents are advised that not withstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Printing Office for the Contract No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM ITEM</th>
<th>E. CONTRACT PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>W15QKN21C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. PREPARED BY</th>
<th>H. DATE</th>
<th>I. APPROVED BY</th>
<th>J. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (6)</td>
<td></td>
<td>(b) (6)</td>
<td></td>
</tr>
</tbody>
</table>

**REMARKS**

All formal communications with the FDA should be provided to BARDA

- Contractor shall notify BARDA of upcoming FDA meeting within (b) (4) of scheduling Type A, B or C meetings OR within (b) (4) of meeting occurrence for ad hoc meetings
- Contractor shall forward initial contractor and FDA-issued draft minutes and final minutes of any meeting with the FDA to BARDA within (b) (4) of receipt
Upon request of the Government, the contractor shall participate in a daily check-in update if necessary with the Project Managers and additional project staff as needed (via teleconference or email). Potential triggers for the check-in include but are not limited to regulatory status changes, manufacturing or distribution problems that will affect delivery.

Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the Government, check-ins may also occur on weekends and on federal holidays, provided at least (b) (4) notice.

- Preparation of materials will not be required but may be provided on an ad hoc basis as data or circumstances occur
- No agenda will be required for the meeting
- No meeting minutes are required
- Contractor will provide bulleted email updates following any call or in lieu of a call by 2PM for that day
## CONTRACT DATA REQUIREMENTS LIST

**A. CONTRACT LINE ITEM NO.**
0001

**B. EXHIBIT**
A

**C. CATEGORY:**
DPI Oil-Wit

**D. SYSTEM ITEM**
Therapeutics

**E. CONTRACT/PR NO.**
W15QKN21C

**F. CONTRACTOR**
Regeneron

---

**1. DATA ITEM NO.**
A007

**2. TITLE OF DATA ITEM**
Monthly Progress Reports

---

**4. AUTHORITY (Data Acquisition Document No.)**
DI-MISC-80711

**5. CONTRACT REFERENCE**
SOW

**6. REQUIRING OFFICE**
BARDA

---

**14. DISTRIBUTION**

<table>
<thead>
<tr>
<th>a. ADDRESS</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td>1</td>
</tr>
<tr>
<td>JPEO CBRND</td>
<td>1</td>
</tr>
</tbody>
</table>

---

**10. FREQUENCY**
see remarks

**12. DATE OF FIRST SUBMISSION**
see remarks

**13. DATE OF SUBSEQUENT SUBMISSION**
see remarks

---

**16. REMARKS**
A consolidated submission of all slides and data presented at the biweekly telecon will serve as the monthly report.

The report only consists of a summary of quantity of product delivered, when and location of the delivery.

- Monthly reports shall be submitted on or before the **(b) (4)** covering the preceding month

---

**G. PREPARED BY**

**H. DATE**

**I. APPROVED BY**

**J. DATE**

---

**TOTAL**
2 0 0
**CONTRACT DATA REQUIREMENTS LIST**

(1 Data Item)

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>TOP X IM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM ITEM</th>
<th>E. CONTRACT PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>W1SQKNz1C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. PREPARED BY</th>
<th>H. DATE</th>
<th>I. APPROVED BY</th>
<th>J. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. DATA ITEM NO.</th>
<th>2. TITLE OF DATA ITEM</th>
<th>3. SUBTITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A008</td>
<td>Milestone Reports</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. AUTHORITY (Data Acquisition Document No.)</th>
<th>5. CONTRACT REFERENCE</th>
<th>6. REQUIRING OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>DI-MISC-80711</td>
<td>SOW</td>
<td>BARDA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>see remarks</td>
<td></td>
<td>see remarks</td>
<td>see remarks</td>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

**REMARKS**

Milestone reports shall be cross-referenced to the Work Breakdown Structure (WBS) and Statement of Work (SOW).

As applicable, an Executive Summary highlighting the progress, issues and relevant manufacturing, non-clinical, clinical and regulatory activities. The Executive Summary should highlight only critical issues for that reporting period and resolution approach,

- limited to 2 pages
- Milestone reports shall be submitted upon the completion of each milestone and include all associated deliverables. The AOR and AO will review the monthly reports with the Awardee and provide feedback
- Awardee shall provide FINAL versions of reports within (b) (4) after receiving BARDA comments/edits

**TOTAL**

2 0 0

**DD FORM 1423-1, FEB 2001**

PREVIOUS EDITION MAY BE USED.
A draft Final Technical Progress Report containing a summation of the work performed over the entire Agreement. This report shall be in sufficient detail to fully describe the progress achieved under all milestones. Report should contain a timeline of originally planned and baselined activities and milestones overlaid with actual progress attained during the Agreement. Descriptions and rationale for activities and milestones that were not completed as planned should be provided. The draft report shall be duly marked as "Draft".

- The Draft Technical Progress Report shall be submitted before the end of the PoP and the Final Technical Progress Report on or before the completion date of the PoP.
- AOR will provide feedback on draft report within of receipt, which the Awarder shall consider incorporating into the Final Report.
**Contract Data Requirements List**

(1 Data Item)

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Respondents are encouraged to suggest additional ways to reduce the public reporting burden. In order to do so please fax comments to 202-395-7222, or email comments to public.info@ sce.osd.mil, and reference OMB No. 0704-0188. Comments should be addressed to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, DC 20503.

The following form is for use in Contract Item No. 0001, A010.

<table>
<thead>
<tr>
<th>A. Contract Line Item No.</th>
<th>B. Exhibit</th>
<th>C. Category:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>Therapeutics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. System Item</th>
<th>E. Contract PR No.</th>
<th>F. Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>W15QKNZIC</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. Prepared By</th>
<th>H. Date</th>
<th>I. Approved By</th>
<th>J. Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The Final Technical Progress Report incorporating feedback received from BARDA and containing a summation of the work performed for the entire agreement PoP. The final report shall document the results of the entire Agreement. The final report shall be duly marked as 'Final'. A cover letter with the report will contain a summary (not to exceed 200 words) of product delivery and distribution achieved during the performance of the Agreement.

- The Final Technical report will include all milestone reports submitted throughout the period of performance and include an overarching executive summary.
**CONTRACT DATA REQUIREMENTS LIST**

- **Form Approved**
  - OMB No. 0704-0188

---

**A. CONTRACT LINE ITEM NO.**
- 0001

**B. EXHIBIT**
- A

**C. CATEGORY:**
- TDP
- IM
- OTHER

**D. SYSTEM ITEM**
- Therapeutics

**E. CONTRACT PR NO.**
- W15QKN21C

**F. CONTRACTOR**
- Regeneron

---

**D. SYSTEM ITEM**
- Therapeutics

**E. CONTRACT PR NO.**
- W15QKN21C

---

The contractor shall submit a detailed spreadsheet regarding critical project materials that are sourced from a location other than the United States, sources, and manufacturing sites, including but not limited to physical locations of sources of raw and processed material by type of material; location and nature of work performed at manufacturing sites; and location and nature of non-clinical and clinical study sites.

The contractor will provide manufacturing reports and manufacturing dose tracking projections/actuals utilizing the "COVID-19 Dose Tracking Templates" or similar, on any contract/agreement that is manufacturing product, including product for clinical trial use. Awardee will submit Product Development Source Material Report:

- Within (b) (4) of Agreement award
- Within (b) (4) of substantive changes are made to sources and/or materials
- Or on the (b) (4) contract anniversary.

- Contractor will update the Dose Tracking Template weekly during manufacturing campaigns and daily during response operations (where a Public Health Emergency has been declared) and COVID-19 response, with the first deliverable submission within 30 days of award/modification. Updates to be provided weekly in advance of commercial-scale manufacturing and daily once material for use in response operations begins manufacture.

- The Government will provide written comments to the Product Development Source Material and Manufacturing Report within (b) (4) after the submission.
- If corrective action is recommended, contractor must address all concerns raised by BARDA in writing.
- Product Development and Source Material report to be submitted via spreadsheet; Dose Tracking can be completed via spreadsheet or other format (e.g. XML or JSON) as agreed to by USG and company.

---

**DD FORM 1423-1, FEB 2001**

**PREVIOUS EDITION MAY BE USED.**

---

**Page 11 of 32**

**Pages**

---

**Addison Professional 8.0**
The contractor shall submit detailed data regarding locations where work will be performed under this contract, including addresses, points of contact, and work performed per location, to include sub-awardees.

Contractor will submit Work Locations Report:
- Within (b)(4) of Agreement award
- Within (b)(4) after a substantive location or capabilities change
- Within (b)(4) of a substantive change if the work performed supports medical countermeasure development that addresses a threat that has been declared a Public Health Emergency by the HHS Secretary or a Public Health Emergency of International Concern (PHEIC) by the WHO.
**A. CONTRACT LINE ITEM NO.** 0001
**B. EXHIBIT** A
**C. CATEGORY:** Therapeutics

<table>
<thead>
<tr>
<th>D. SYSTEM ITEM</th>
<th>E. CONTRACT PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>A013</td>
<td>W1SQKN21C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

**4. AUTHORITY (Data Acquisition Document No.)**
DI-TCSP-82040

**5. CONTRACT/PROJ NO.** W1SQKN21C

**6. REQUIRING OFFICE** BARDA

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>see remarks</td>
<td></td>
<td>see remarks</td>
<td>see remarks</td>
</tr>
</tbody>
</table>

**14. DISTRIBUTION**

- **a. ADDRESSEE**
  - BARDA
  - JPEOCBRND
- **b. COPIES**
  - Draft
  - Final
  - Reg
  - Repro

**16. REMARKS**
A pandemic facility and/or operational management plan including change procedures from normal to pandemic operations contractor will prepare an operational plan to continue operations in the event of a declared pandemic emergency.

Awardee will submit Pandemic Management Plan:
- Draft within (b) (D) of award
- Final within (b) (D) of award
## Distribution Concept of Operations

The contractor shall distribute product at upon Government direction and pursuant to the Government’s allocation determinations. BARDA, and MCM Manufacturers play an important role in the distribution of therapies to the American people under a nationwide response. BARDA will work with the manufacturer to monitor what is in the manufacturing pipeline using the enclosed dose tracking templates (see above). Awarded will relay final drug product information as it is being released to the BARDA/ASPR for allocation and ordering by state public health departments. This information will be returned to BARDA, the awardee and distributor. Distributors will use that information to ship therapeutics in bulk to sites of administration or user.

Provide the following information in order to coordinate the movement and delivery of antibody from manufacturing locations sites of administration or user:

- **Points of Contact** information (name, title, phone, email) for manufacturing / supply chain personnel for each manufacturing, CMO, storage and distribution locations:
  - Head of Manufacturing
  - Production Planning
  - Logistics
  - Distribution
  - Labeling

- **Therapeutic labeling, packaging and distribution information** as soon as it becomes available. At a minimum, include the following:
  - **Primary Container Information**
    - Number of doses per primary container
    - Unit of Sale (carton, box, package, other)
    - Quantity per Unit of Sale
    - National Drug Code (NDC) or NDC-like code under EUA
    - Unit of Sale dimensions (H,W,L)
    - Unit of Sale weight
  - **Intermediate Package**
    - Intermediate Package dimensions
    - Intermediate Package weight
  - **Quantity Unit of Sale per pallet**
  - **Storage Requirements**
  - **Stability Information**
  - Obtain concurrence on planned shipment protocols prior to transport

- If therapeutic will require ultra-cold storage temperatures at the designated distribution centers, products should be packaged in 10-dose units to facilitate pick/pack process and reduce exposure of workers to ultra-cold temperatures.

- Include the following DSCSA data elements, TI, TH and TS in packing lists.

- Include the Agreement number on the packing list for all shipments.

- Include a copy of the MSDS (with QR code) in the packing list envelope with each shipment.

- Send EDI 856 Advanced Shipment Notice for all products shipped to a USG directed location. Send electronic/scanned copies of all bulk shipment related documents to the AOR for three-way matching on the day shipment occurs.
### CONTRACT DATA REQUIREMENTS LIST

(1 Data Item)

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

**A. CONTRACT LINE ITEM NO.**

0001

**B. EXHIBIT**

A

**C. CATEGORY:**

TDP

**D. SYSTEM/ITEM**

Therapeutics

**E. CONTRACT/PR NO.**

W15QKN21C

**F. CONTRACTOR**

Regeneron

**1. DATA ITEM NO.**

A015

**2. TITLE OF DATA ITEM**

Distribution Plan

**3. SUBTITLE**

**4. AUTHORITY** (Data Acquisition Document No.)

DI-TCSP-82040

**5. CONTRACT REFERENCE**

SOW

**6. REQUIRING OFFICE**

BARDA

**7. DD 250 REQ**

**8. APP CODE**

**9. DIST STATEMENT REQUIRED**

**10. FREQUENCY**

see remarks

**11. AS OF DATE**

**12. DATE OF FIRST SUBMISSION**

see remarks

**13. DATE OF SUBSEQUENT SUBMISSION**

see remarks

**14. DISTRIBUTION**

<table>
<thead>
<tr>
<th>a. ADDRESSEE</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td>1</td>
</tr>
<tr>
<td>JPEO CBRND</td>
<td>1</td>
</tr>
</tbody>
</table>

**15. TOTAL**

1

**16. REMARKS**

This plan shall describe the Awardee’s process to distribute (according to Government directed allocation) EUA-or BLA-approved product to point of care facilities, necessary to meet the Government’s need for administration. The plan shall comply with applicable provisions of the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov 27, 2013), taking into account FDA’s regular guidance for the COVID-19 public health response. The plan may include details regarding storage and quality assurance of product prior to allocation.

- **Within [b](4) of award**

**17. PRICE GROUP**

**18. ESTIMATED TOTAL PRICE**
**CONTRACT DATA REQUIREMENTS LIST**

(1 Data Item)

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

A. CONTRACT LINE ITEM NO. 0001

B. EXHIBIT

C. CATEGORY: TDP X TM OTHER

---

D. SYSTEM/ITEM Therapeutics

E. CONTRACT/PR NO. W15QKN21C

F. CONTRACTOR Regeneron

---

1. DATA ITEM NO. A016

2. TITLE OF DATA ITEM Manufacturing Development Plan

3. SUBTITLE

4. AUTHORITY (Data Acquisition Document No.) DI-TCSP-82040

5. CONTRACT REFERENCE SOW

6. REQUIRING OFFICE BARDA

---

7. DD 250 REQ see remarks

8. APP CODE see remarks

9. DIST STATEMENT REQUIRED see remarks

10. FREQUENCY see remarks

11. AS OF DATE see remarks

12. DATE OF FIRST SUBMISSION see remarks

13. DATE OF SUBSEQUENT SUBMISSION see remarks

---

14. DISTRIBUTION

<table>
<thead>
<tr>
<th>a. ADDRESSEE</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td>1</td>
</tr>
<tr>
<td>JPEOCBRND</td>
<td>1</td>
</tr>
</tbody>
</table>

---

15. TOTAL 2 0 0

---

16. REMARKS

For products that have received EUA authorization, the plan shall describe any planned improvements to the manufacturing process, formulation, administration, or presentation of the product, including but not limited to dosing, stability, route of administration, changes to the label, or packaging improvements. Plan shall cover the length of the period of performance and may be updated as needed at regular intervals to be established by AOR. For clarity, the agreement is not for research, development or experimental work and, therefore, the activities described in the plan are being performed outside of the agreement. Plan will be delivered electronically within (b) (6) of the Agreement award to the AOR and AO.

---

G. PREPARED BY (b) (6)

H. DATE

I. APPROVED BY (b) (6)

J. DATE

DD FORM 1423-1, FEB 2001
Plan may include, but is not limited to, the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.

- Plan will be delivered electronically within (5) (4) of Agreement award to the AO and AOR.
The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>Therapeutics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM/ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>A018</td>
<td>W15QKNZ1C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. DATA ITEM NO.</th>
<th>2. TITLE OF DATA ITEM</th>
<th>3. SUBSTITUTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A018</td>
<td>Quality Agreement</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. AUTHORITY (Data Acquisition Document No.)</th>
<th>5. CONTRACT/REFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>contractor format acceptable</td>
<td>SOW</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. REQUIRING OFFICE</th>
<th>7. DD 250 REQ</th>
<th>8. APP CODE</th>
<th>9. DIST STATEMENT REQUIRED</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10. FREQUENCY</th>
<th>11. AS OF DATE</th>
<th>12. DATE OF FIRST SUBMISSION</th>
<th>13. DATE OF SUBSEQUENT SUBMISSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>see remarks</td>
<td></td>
<td>see remarks</td>
<td>see remarks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. DISTRIBUTION</th>
<th>a. ADDRESSEE</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>JPEO CBRND</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15. TOTAL</th>
<th>16. REMARKS</th>
</tr>
</thead>
</table>
| 2         | Agreement will determine the conditions of acceptance by the USG of the purchased product. No product will be accepted by the USG until a quality agreement is in place. 
Agreement will be signed by the USG and the manufacturer within [B] of Agreement award. 
Agreement will be delivered electronically to the AO and AOR. |

<table>
<thead>
<tr>
<th>G. PREPARED BY</th>
<th>H. DATE</th>
<th>I. APPROVED BY</th>
<th>J. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (6)</td>
<td></td>
<td>(b) (6)</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** The form includes additional sections and tables that are not fully transcribed here due to the limitations of text representation. For a complete view, the full form is recommended.
<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>IM OTHER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM/ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>W15QKN21C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. PREPARED BY</th>
<th>H. DATE</th>
<th>I. APPROVED BY</th>
<th>J. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (6)</td>
<td></td>
<td>(b) (6)</td>
<td></td>
</tr>
</tbody>
</table>

**Remarks:**

- Certificate of Analysis
- Certificate of Compliance
  - as soon as practicable, prior to delivery

**Distribution:**

- BARDA: 1
- JPEO CBRND: 1

**Total:**

- 2
  - Draft: 0
  - Final: 0

DD FORM 1423-1, FEB 2001
CONTRACT DATA REQUIREMENTS LIST
(1 Data Item)

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and submitting the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directors (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract PR No. listed in Block E.

A. CONTRACT LINE ITEM NO. 0001
B. EXHIBIT A
C. CATEGORY: Therapeutics

D. SYSTEM ITEM

E. CONTRACT PR NO. W15QKN21C
F. CONTRACTOR Regeneron

1. DATA ITEM NO. A020
2. TITLE OF DATA ITEM Manufacturing and Distribution Records
3. SUBTITLE

D. AUTHORITY (Data Acquisition Document No.)
contractor format acceptable

E. CONTRACT REFERENCE SOW

F. CONTRACTOR

6. REQUIRING OFFICE BARDA

7. DD 250 FIEQ
9. DISTRIBUTION
11. AS OF DATE
13. DATE OF SUBSEQUENT SUBMISSION see remarks

15. TOTAL 2 0 0

16. REMARKS
(1) Certificate of Analysis; (2) Certificate of Conformance/Compliance; and (3) a sample label and carton from production run for drug substance and drug product will be delivered in a timely manner.

Documentation to be reviewed by USG and comments adjudicated prior to close delivery

G. PREPARED BY
H. DATE
I. APPROVED BY
J. DATE

DD FORM 1423-1, FEB 2001

PREVIOUS EDITION MAY BE USED.
Develop a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the Government requirement. This plan shall establish security practices and procedures that demonstrate how the Awardee will meet and adhere to the security requirements outlined below prior to the commencement of product manufacturing, and shall be delivered to the Government within the time period referenced in the Award. The Awardee shall also use commercially reasonable efforts to ensure all subawardees, consultants, researchers, etc. performing work on behalf of this effort, comply with all Government security requirements and Awardee security plans. The Awardee will flow-down the provisions of the Security Plan to (i) all sub-agreements/contracts executed after the Execution Date, and (ii) all sub-agreements/executed prior to the Execution Date which cover manufacturing/fill/finish/storage activities under this Agreement, provided that in no event will the Awardee be required to flow-down any provisions to any sub-awardee which has a preexisting direct relationship with the Government. The Awardee will have a period of (b)(4) to amend any existing agreements to reflect these flow-down requirements or, in the alternative, to demonstrate the sub-awardee’s material compliance with any such flow-down requirements.

The Government will review in detail and submit comments within (b)(4) to the Agreements Officer (AO) to be forwarded to the Awardee. The Awardee shall review the Draft Security Plan comments, and, submit a Final Security Plan to the U.S. Government within (b)(4) after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined by the Government.

Upon completion of initiating all security measures, the Awardee shall supply to the Agreements Officer a letter certifying compliance to the elements outlined in the Final Security Plan.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>0001</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. EXHIBIT</td>
<td>A</td>
</tr>
<tr>
<td>C. CATEGORY:</td>
<td>TDM</td>
</tr>
<tr>
<td>D. SYSTEM ITEM:</td>
<td>Therapeutics</td>
</tr>
<tr>
<td>E. CONTRACT PR NO.</td>
<td>W1S0KNZ1C</td>
</tr>
<tr>
<td>F. CONTRACTOR:</td>
<td>Regeneron</td>
</tr>
<tr>
<td>G. PREPARED BY:</td>
<td>(b)(6)</td>
</tr>
<tr>
<td>H. DATE</td>
<td></td>
</tr>
<tr>
<td>I. APPROVED BY:</td>
<td>(b)(6)</td>
</tr>
<tr>
<td>J. DATE</td>
<td></td>
</tr>
</tbody>
</table>

**Security Plan**

- Title: Security Plan
- Subtitle: (Data Acquisition Document No.)
- Authority: Data Acquisition Document No.
- Format: acceptable
- Reference: SOW
- Office: BARDA
- App Code: 11
- As of Date: 14
- Address: BARDA
- Copies: Draft 1
- Distribution: Final 1
- Remarks: See remarks

**Comments**

- Develop a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the Government requirement. This plan shall establish security practices and procedures that demonstrate how the Awardee will meet and adhere to the security requirements outlined below prior to the commencement of product manufacturing, and shall be delivered to the Government within the time period referenced in the Award. The Awardee shall also use commercially reasonable efforts to ensure all subawardees, consultants, researchers, etc. performing work on behalf of this effort, comply with all Government security requirements and Awardee security plans. The Awardee will flow-down the provisions of the Security Plan to (i) all sub-agreements/contracts executed after the Execution Date, and (ii) all sub-agreements/executed prior to the Execution Date which cover manufacturing/fill/finish/storage activities under this Agreement, provided that in no event will the Awardee be required to flow-down any provisions to any sub-awardee which has a preexisting direct relationship with the Government. The Awardee will have a period of (b)(4) to amend any existing agreements to reflect these flow-down requirements or, in the alternative, to demonstrate the sub-awardee’s material compliance with any such flow-down requirements.

- The Government will review in detail and submit comments within (b)(4) to the Agreements Officer (AO) to be forwarded to the Awardee. The Awardee shall review the Draft Security Plan comments, and, submit a Final Security Plan to the U.S. Government within (b)(4) after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined by the Government.

- Upon completion of initiating all security measures, the Awardee shall supply to the Agreements Officer a letter certifying compliance to the elements outlined in the Final Security Plan.
A comprehensive Supply Chain Resiliency Program that provides identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods. A critical component is defined as any material that is essential to the product or the manufacturing process associated with that product. Included in the definition are consumables and disposables associated with manufacturing, NOT included in the definition are facility and capital equipment.

Consideration of critical components includes the evaluation and potential impact of raw materials, excipients, active ingredients, substances, pieces, parts, software, firmware, labeling, assembly, testing, analytical and environmental componentry, reagents, or utility materials which are used in the manufacturing of a drug, cell banks, seed stocks, devices and key processing components and equipment.

A clear example of a critical component is one where a sole supplier is utilized.

The contractor shall identify key equipment suppliers, their locations, local resources, and the associated control processes at the time of award. This document shall address planning and scheduling for active pharmaceutical ingredients, upstream, downstream, component assembly, finished drug product and delivery events as necessary for the delivery of product.

- Communication for these requirements shall be updated as part of an annual review, or as necessary, as part of regular contractual communications.
- For upstream and downstream processing, both single-use and re-usable in-place processing equipment, and manufacturing disposables also shall be addressed. For finished goods, the inspection, labeling, packaging, and associated machinery shall be addressed taking into account capacity capabilities.
- The focus on the aspects of resiliency shall be on critical components and aspects of complying with the Agreement delivery schedule. Delivery methods shall be addressed, inclusive of items that are foreign-sourced, both high and low volume, which would significantly affect throughput and adherence to the contractually agreed deliveries.

The Awardee shall articulate in the plan, the methodology for inventory control, production planning, scheduling processes and ordering mechanisms, as part of those agreed deliveries.

a) Production rates and lead times shall be understood and communicated to the...
### CONTRACT DATA REQUIREMENTS LIST

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
<th>D. SYSTEM ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>TDP ×</td>
<td>Therapeutics</td>
<td>W15QKN21C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

#### 16. REMARKS (Continued)

Agreements Officer or the Agreements Officer’s Representative as necessary.

b) Production throughput critical constraints should be well understood by activity and by design, and communicated to contractual personnel. As necessary, communication should focus on identification, exploitation, elevation, and secondary constraints of throughput, as appropriate.

Reports for critical items should include the following information:

I. Critical Material  
II. Vendor  
III. Supplier, Manufacturing / Distribution Location  
IV. Supplier Lead Time  
V. Shelf Life  
VI. Transportation / Shipping restrictions

The AO and AOR reserve the right to request un-redacted copies of technical documents provided in response to this subsection, during the period of performance, for distribution within the Government.

Documents shall be provided within [D (4)] after AO issues the request. The contractor may arrange for additional time if deemed necessary, and agreed to by the AO. The Government will have Limited Rights in any documents provided under this subsection.

- Delivery of plan is within [D (4)] of award
Detailed data regarding project materials, sources, and manufacturing sites, including but not limited to: physical locations of sources of raw and processed material by type of material, location and nature of work performed at manufacturing, processing, and fill/finish sites; and location and nature of non-clinical and clinical studies sites.

- Within the award
- The Government may provide a table in tabular format for Awardee to be used to submit such data, intended to ensure material development, which would include but not be limited to the following:
  1) Storage/inventory of ancillary materials (vials, needles, syringes, etc.)
  2) Shipment of ancillary materials (vials, needles, syringes, etc.)
  3) Disposal of ancillary materials (vials, needles, syringes, etc.)
  4) Seed development or other starting material manufacturing
  5) Bulk drug substance and/or adjuvant production
  6) Fill, finish, and release of product or adjuvant
  7) Storage/inventory of starting materials, bulk substance, or filled/final product or adjuvant
  8) Stability information of bulk substance and/or finished material
  9) Shipment of bulk substance of final material
  10) Disposal of bulk substance or final material

G. PREPARED BY (b)(6)  H. DATE  I. APPROVED BY (b)(6)  J. DATE
## CONTRACT DATA REQUIREMENTS LIST

(1 Data Item)

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Office of the President (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PS No. listed in Block E.

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>DRX IM OTHER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. SYSTEM ITEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>W15QKNZ1C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. AUTHORITY (Data Acquisition Document No.)</th>
<th>H. CONTRACT REFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>DI-SBSS-81921</td>
<td>SOW</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I. REQUIRING OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>J. DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
</tr>
</tbody>
</table>

**Remarks:**
Contractor shall accommodate periodic or ad hoc site visits by BARDA. If BARDA, the contractor, or other parties identifies any issues during an audit, the contractor shall capture the issues, identify potential solutions, and provide a report to BARDA. If issues are identified during the audit, contractor shall submit a report to BARDA detailing the findings and corrective action(s) within 15 days of the audit. AOR and AO will review the report and provide a response to the Contractor within 10 days. Once corrective action is completed, the Awardee will provide a final report to BARDA.
In the event of an FDA inspection that occurs in relation to this contract and for the product, or for any other FDA inspection that has the reasonable potential to impact the performance of this contract, the Awardee shall provide the USG with an exact copy (non-redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR). The Contractor shall also provide copies of any FDA audits received from subawardees that occur as a result of this contract or for this product.

- Contractor shall notify AO and AOR within (b) (4) of a scheduled FDA audit or within (b) (4) of an ad hoc site visit/audit if the FDA does not provide advanced notice.
- Contractor shall also provide copies of any FDA audit report received from subawardees that occur as a result of this contract or for this product within (b) (4) of receiving correspondence from the FDA or third party.
- Within (b) (4) of receiving correspondence from the FDA, contractor shall provide AOR with a plan for addressing areas of nonconformance, if any are identified.
### CONTRACT DATA REQUIREMENTS LIST

**Form Approved OMB No. 0704-0188**

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services

**A. CONTRACT LINE ITEM NO.**

0001

**B. EXHIBIT**

A

**C. CATEGORY:**

TPD [ ] IM [ ] OTHER [ ]

**D. SYSTEM/ITEM**

Therapeutics

**E. CONTRACT/PR NO.**

W15QKN21C

**F. CONTRACTOR**

Regeneron

<table>
<thead>
<tr>
<th>1. DATA ITEM NO.</th>
<th>2. TITLE OF DATA ITEM</th>
<th>3. SUBSTITUTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A026</td>
<td>QA Audits</td>
<td></td>
</tr>
</tbody>
</table>

**4. AUTHORITY (Data Acquisition Document No.)**

DI-SBSS-8121

**5. CONTRACT REFERENCE**

SOW

**6. REQUIRING OFFICE**

BARDA

**7. DD 250 REG.**

DI-SBSS-8121

**9. DISTRIBUTION STATEMENT**

SOW

**10. FREQUENCY**

see remarks

**12. DATE OF FIRST SUBMISSION**

see remarks

**14. DISTRIBUTION**

a. ADDRESSEE Draft Final
   - BARDA
   - JPEO CBRND

**16. REMARKS**

BARDA reserves the right to participate in QA audits performed by the contractor. Upon completion of the audit/site visit the contractor shall provide a report capturing the findings, results, and next steps in proceeding with the subawardee. If action is requested of the subawardee, detailed concerns for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report, must be provided to BARDA. The contractor shall provide responses from the subawardees to address these concerns and plans for corrective action.

- Contractor shall notify AO and AOR a minimum of [b] 4 in advance of upcoming, audit/site visits of subawardees
- Contractor shall notify the AOR and AO within [b] 4 of report completion
- AOR and AO will review the report and provide a response to the contractor within [b] 4

**18. TOTAL**

2 0 0

**G. PREPARED BY**

(b) 6

**H. DATE**

(b) 6

**I. APPROVED BY**

(b) 6

**J. DATE**

DD FORM 1423-1, FEB 2001

Previous Edition may be Used.

Page 27 of 32 Pages
## CONTRACT DATA REQUIREMENTS LIST

**1 Data Item**

<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
<th>D. SYSTEM/ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>Regulatory documents</td>
<td>Therapeutics</td>
<td>W15QKN21C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

### 1. DATA ITEM NO. A027

**2. TITLE OF DATA ITEM**

*FDA Submissions*

**3. SUBTITLE**

*Draft Acquisition Document No.*

**4. AUTHORITY (Data Acquisition Document No.)**

*DI-TCSP-82040*

**5. CONTRACT REFERENCE**

*SOW*

**6. REQUIRING OFFICE**

*BARDA*

**7. Freqency**

*see remarks*

**8. APPL CODE**

*see remarks*

**9. STATEMENT REQUIRED**

*see remarks*

**10. AS OF DATE**

*see remarks*

**11. DATE OF FIRST SUBMISSION**

*see remarks*

**12. DATE OF SUBSEQUENT SUBMISSION**

*see remarks*

**13. ADDRESSSEE**

*BARDA*

**14. DISTRIBUTION**

<table>
<thead>
<tr>
<th>a. ADDRESSSEE</th>
<th>b. COPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td>1</td>
</tr>
</tbody>
</table>

**15. TOTAL** 2

### REMARKS

The contractor shall provide BARDA the opportunity to review and comment upon all draft submissions before submission to the FDA with regard to the product(s) of this contract. Contractor shall provide BARDA with an electronic copy of the final FDA submission. All documents shall be duly marked as either "Draft" or "Final".

Contractor shall use reasonable effort to submit draft FDA submissions to BARDA at least **(b) (4)** prior to FDA submission or within a shorter timeframe upon agreement between Awardee and AOR.

- BARDA will provide feedback to contractor within **(b) (4)** of receipt or within a shorter timeframe as agreed upon by Awardee and AOR.
- The contractor must address, in writing, its consideration of all concerns raised by BARDA prior to FDA submission.
- Final FDA submissions shall be submitted to BARDA concurrently or as soon as practical after submission to the FDA.

Note: Given the urgency associated with the pandemic, the above timelines will be adhered to if and to the extent practicable under the circumstances.

**G. PREPARED BY**

**(b) (6)**

**H. DATE**

**(b) (6)**

**I. APPROVED BY**

**(b) (6)**

**J. DATE**
<table>
<thead>
<tr>
<th>A. CONTRACT LINE ITEM NO.</th>
<th>B. EXHIBIT</th>
<th>C. CATEGORY:</th>
<th>D. SYSTEM ITEM</th>
<th>E. CONTRACT/PR NO.</th>
<th>F. CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>A</td>
<td>Regulatory documents</td>
<td>Therapeutics</td>
<td>W15QN21C</td>
<td>Regeneron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. DATA ITEM NO.</th>
<th>2. TITLE OF DATA ITEM</th>
<th>3. SUBTITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A028</td>
<td>EUA filing</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. AUTHORITY (Data Acquisition Document No.)</th>
<th>5. CONTRACT REFERENCE</th>
<th>6. REQUIRING OFFICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>contractor format acceptable</td>
<td>SOW</td>
<td>BARDA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10. FREQUENCY</th>
<th>12. DATE OF FIRST SUBMISSION</th>
<th>13. DATE OF SUBSEQUENT SUBMISSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>see remarks</td>
<td>see remarks</td>
<td>see remarks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16. REMARKS</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Awardee shall provide a copy of any request for EUA submitted to the FDA</td>
</tr>
<tr>
<td>Upon award</td>
</tr>
</tbody>
</table>

G. PREPARED BY (b) (6)

H. DATE

I. APPROVED BY (b) (6)

J. DATE
The awardee shall submit Public Law 115-92 Sponsor Authorization Letter in the Contractor's format that will be delivered to the designated OWS POC(s).

- Within **(B) (4)** of award
### CONTRACT DATA REQUIREMENTS LIST

#### A. CONTRACT LINE ITEM NO. 0001
#### B. EXHIBIT A
#### C. CATEGORY: Other

<table>
<thead>
<tr>
<th>D. SYSTEM ITEM</th>
<th>E. CONTRACT/PR NO. W15QKN21C</th>
<th>F. CONTRACTOR Regeneron</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>1. DATA ITEM NO.</th>
<th>2. TITLE OF DATA ITEM Press Releases</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3. AUTHORITY Data Acquisition Document No. 1</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. AUTHORITY Data Item No. 1</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>5. CONTRACT/PR NO. W15QKN21C</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>6. CONTRACT/PR NO. W15QKN21C</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>7. CONTRACT/PR NO. W15QKN21C</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. APP CODE A030</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>9. DIST STATEMENT REQUIRED</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>10. FREQUENCY see remarks</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>11. AS OF DATE see remarks</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>12. DATE OF FIRST SUBMISSION see remarks</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>13. DATE OF SUBSEQUENT SUBMISSION see remarks</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>14. CONTRACT REFERENCE SOW</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>15. DISTRIBUTION</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>a. ADDRESSEE BARDA</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>b. COPIES</th>
</tr>
</thead>
</table>

16. REMARKS

Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases. Contractor shall ensure that the AO has received and approved an advanced copy of any press release to this contract not less than 4 days prior to the issuance of the press release.

- If corrective action is required, the contractor agrees to accurately and factually represent the work conducted under this contract in all press releases.
- Any final press releases shall be submitted to BARDA no later than 4 days prior to its release.

<table>
<thead>
<tr>
<th>17. PRICE GROUP</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>18. ESTIMATED TOTAL PRICE</th>
</tr>
</thead>
</table>

G. PREPARED BY (b) (6)

H. DATE (b) (6)

I. APPROVED BY (b) (6)

J. DATE (b) (6)
### FOR GOVERNMENT PERSONNEL

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Self-explanatory.</td>
</tr>
<tr>
<td>B</td>
<td>Self-explanatory.</td>
</tr>
<tr>
<td>C</td>
<td>Mark (X) appropriate category: TDP - Technical Data Package; TM - Technical Manual; Other - other category of data, such as &quot;Providing,&quot; &quot;Configuration Management,&quot; etc.</td>
</tr>
<tr>
<td>D</td>
<td>Enter name of system/item being acquired that data will support.</td>
</tr>
<tr>
<td>E</td>
<td>Self-explanatory (to be filled in after contract award).</td>
</tr>
<tr>
<td>F</td>
<td>Self-explanatory (to be filled in after contract award).</td>
</tr>
<tr>
<td>G</td>
<td>Signature of preparer of CDRL.</td>
</tr>
<tr>
<td>H</td>
<td>Date CDRL was prepared.</td>
</tr>
<tr>
<td>I</td>
<td>Signature of CDRL approval authority.</td>
</tr>
<tr>
<td>J</td>
<td>Date CDRL was approved.</td>
</tr>
<tr>
<td>1</td>
<td>See DoD FAR Supplement Subpart 4.7 for proper numbering.</td>
</tr>
<tr>
<td>2</td>
<td>Enter title as it appears on data acquisition document cited in Item 4.</td>
</tr>
<tr>
<td>3</td>
<td>Enter subtitle of data item for further definition of data item (optional entry).</td>
</tr>
<tr>
<td>4</td>
<td>Enter Data Item Description (DID) number, military specification number, or military standard number listed in DoD 5010.12-L (AMSFL), or one-time DID number, that defines data content and format requirements.</td>
</tr>
<tr>
<td>5</td>
<td>Enter reference to tasking in contract that generates requirement for the data item (e.g., Statement of Work paragraph number).</td>
</tr>
<tr>
<td>6</td>
<td>Enter technical office responsible for ensuring adequacy of the data item.</td>
</tr>
<tr>
<td>7</td>
<td>Specify requirement for inspection/acceptance of the data item by the Government.</td>
</tr>
<tr>
<td>8</td>
<td>Specify requirement for approval of a draft before preparation of the final data item.</td>
</tr>
<tr>
<td>9</td>
<td>For technical data, specify requirement for contractor to mark the appropriate distribution statement on the data (ref. DoDD 5230.24).</td>
</tr>
<tr>
<td>10</td>
<td>Specify number of times data items are to be delivered.</td>
</tr>
<tr>
<td>11</td>
<td>Specify as of date of data item, when applicable.</td>
</tr>
<tr>
<td>12</td>
<td>Specify when first submittal is required.</td>
</tr>
<tr>
<td>13</td>
<td>Specify when subsequent submittals are required, when applicable.</td>
</tr>
<tr>
<td>14</td>
<td>Enter addressees and number of draft/final copies to be delivered to each addressee. Explain reproducible copies in Item 16.</td>
</tr>
<tr>
<td>15</td>
<td>Enter total number of draft/final copies to be delivered.</td>
</tr>
<tr>
<td>16</td>
<td>Use for additional clarifying information for Items 1 through 15. Examples are: Tailoring of documents cited in Item 4; Clarification of submittal dates in Items 12 and 13; Explanation of reproducible copies in Item 14.; Desired medium for delivery of the data item.</td>
</tr>
</tbody>
</table>

### FOR THE CONTRACTOR

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Specify appropriate price group from one of the following groups of effort in developing estimated prices for each data item listed on the DD Form 1423.</td>
</tr>
<tr>
<td>a</td>
<td>Group I. Definition - Data which is not otherwise essential to the contractor's performance of the primary contracted effort (production, development, testing, and administration) but which is required by DD Form 1423.</td>
</tr>
<tr>
<td></td>
<td>Estimated Price - Costs to be included under Group I are those applicable to preparing and assembling the data item in conformance with Government requirements, and the administration and other expenses related to reproducing and delivering such data item to the Government.</td>
</tr>
<tr>
<td>b</td>
<td>Group II. Definition - Data which is essential to the performance of the primary contracted effort but the contractor is required to perform additional work to conform to Government requirements with regard to depth of content, format, frequency of submittal, preparation, control, or quality of the data item.</td>
</tr>
<tr>
<td></td>
<td>Estimated Price - Costs to be included under Group II are those incurred over and above the cost of the essential data item without conforming to Government requirements, and the administrative and other expenses related to reproducing and delivering such data item to the Government.</td>
</tr>
<tr>
<td>c</td>
<td>Group III. Definition - Data which the contractor must develop for his internal use in performance of the primary contracted effort and does not require any substantial change to conform to Government requirements with regard to depth of content, format, frequency of submittal, preparation, control, and quality of the data item.</td>
</tr>
<tr>
<td></td>
<td>Estimated Price - Costs to be included under Group III are those incurred over and above the cost of the essential data item without conforming to Government requirements, and the administrative and other expenses related to reproducing and delivering such data item to the Government.</td>
</tr>
<tr>
<td>d</td>
<td>Group IV. Definition - Data which is developed by the contractor as part of his normal operating procedures and his effort in supplying these data to the Government is minimal.</td>
</tr>
<tr>
<td></td>
<td>Estimated Price - Group IV items should normally be shown on the DD Form 1423 at no cost.</td>
</tr>
<tr>
<td>18</td>
<td>For each data item, enter an amount equal to that portion of the total price which is estimated to be attributable to the production or development for the Government of that item of data. These estimated data prices shall be developed only from those costs which will be incurred as a direct result of the requirement to supply the data, over and above those costs which would otherwise be incurred in performance of the contract if no data were required. The estimated data prices shall not include any amount for rights in data. The Government's right to use the data shall be governed by the pertinent provisions of the contract.</td>
</tr>
</tbody>
</table>
## DISCLOSURE OF LOBBYING ACTIVITIES

OMB Control Number: 4040-0013
Expiration Date: 2/28/2022
Complete this form to disclose lobbying activities pursuant to 31 U.S.C. 1352

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a. contract</td>
<td>a. bid/offer/application</td>
<td>a. initial filing</td>
</tr>
<tr>
<td>b. grant</td>
<td>b. initial award</td>
<td>b. material change</td>
</tr>
<tr>
<td>c. cooperative agreement</td>
<td>c. post-award</td>
<td></td>
</tr>
<tr>
<td>d. loan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. loan guarantee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>f. loan insurance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Name and Address of Reporting Entity:</th>
<th>5. If Reporting Entity in No.4 is Subawardee, Enter Name and Address of Prime:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prime: Regeneron Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Street 1: 777 Old Saw Mill River Road</td>
<td></td>
</tr>
<tr>
<td>City: Tarrytown</td>
<td></td>
</tr>
<tr>
<td>State: NY</td>
<td></td>
</tr>
<tr>
<td>Zip: 10591</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. Federal Department/Agency:</th>
<th>7. Federal Program Name/Description:</th>
</tr>
</thead>
<tbody>
<tr>
<td>DoH/BAH/DA</td>
<td>COVID Therapeutics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. Federal Action Number, if known:</th>
<th>9. Award Amount, if known:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Applicable</td>
<td>$ 2,625,000,000.00</td>
</tr>
</tbody>
</table>

10. a. Name and Address of Lobbying Registrant:

<table>
<thead>
<tr>
<th>Prefix</th>
<th>* First Name</th>
<th>Not Applicable</th>
<th>Middle Name</th>
<th>Suffix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Last Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street 1</th>
<th>Street 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>State</td>
</tr>
</tbody>
</table>

b. Individual Performing Services (including address if different from No. 10a):

<table>
<thead>
<tr>
<th>Prefix</th>
<th>* First Name</th>
<th>Not Applicable</th>
<th>Middle Name</th>
<th>Suffix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Last Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street 1</th>
<th>Street 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>State</td>
</tr>
</tbody>
</table>

11. Information requested through this form is authorized by title 31 U.S.C. section 1352. This disclosure of lobbying activities is a material representation of fact upon which reliance was placed by the tiers above when the transaction was made or entered into. This disclosure is required pursuant to 31 U.S.C. 1352. This information will be reported to the Comptroller General. Any false disclosure shall be subject to a civil penalty of not less than $10,000.

**Signature:**

**Name:**

**Title:**

**Telephone No.:**

**Date:** 01/04/2021

STANDARD FORM 17 (REV. 7/1997)

Federal Use Only:
SMALL BUSINESS SUBCONTRACTING PLAN

(Model Outline* — Template Revised 4/28/2020)

* This template is a suggested model for use when formulating a subcontracting plan pursuant to the requirements at FAR 52.219-9(d). While this model plan has been designed to be consistent with FAR 52.219-9, other formats may be acceptable. However, failure to include the essential information as set forth in this model may be cause for either a delay in acceptance or the rejection of an offer where the clause is applicable. Further, the use of this model is not intended to waive other requirements that may be applicable under FAR 52.219-9 or that may appear in the Government’s solicitation. "SUBCONTRACT," as used in 52.219-9, refers to your external company spend, meaning any agreement (other than one involving an employer-employee relationship) entered into by a federal government prime contractor or subcontractor calling for supplies or services required for performance of the contract or subcontract.

SUBCONTRACTING PLAN PERIOD: January 1, 2021 - December 31, 2021

Individual plans should cover the entire period of performance, and commercial plans should coincide with the company’s fiscal year. In the event your company’s fiscal year is for a period that will end before the contract periods of any federal contracts you hold which include the requirement to have a small business subcontracting plan, you will be required to submit a new subcontracting plan for approval thirty (30) days prior to expiration of the existing subcontracting plan. In the event an acceptable plan cannot be negotiated prior to expiration of the existing subcontracting plan, your contract(s) may be terminated.

DATE SUBMITTED: November 30th, 2020

NAME OF PLANHOLDER: Regeneron Pharmaceuticals Inc.

SUBSIDIARIES INCLUDED: [ ]

ADDRESS: 777 Old Saw Mill River Road
Tarrytown, NY 10591

ITEM/SERVICE TYPE: Drugs and Pharmaceutical Products

1. TYPE OF PLAN

Select only one of the following plan types (a or b), listing the total estimated dollar value of all planned subcontracting (to all types of business concerns, both large and small). Per 13 CFR 125.3(a)(1)(iii), the following categories should not be included in the total subcontracting spend base in #1, the proposed goals in #2, nor in the categories of spend listed in #3: internally generated costs such as salaries and wages; employee insurance; other employee benefits; payments for petty cash; depreciation; interest; income taxes; property taxes; lease payments; bank fees; fines, claims, and dues; Original Equipment Manufacturer relationships during warranty periods (negotiated up front with product); utilities such as electricity, water, sewer, and other services purchased from a municipality or solely authorized by the municipality to provide those services in a particular geographical region; and philanthropic contributions. Utility companies may be eligible for additional exclusions unique to their industry, which may be approved by the contracting officer on a case-by-case basis.

a) Individual Plan (This Contract Only) Contract #/Solicitation #

Total value of projected subcontracts (both large and small businesses)
Base Period $ _____ 5-Year Option $ _____
Total Contract Value (including options) $ _____
*Separate goals must be included for each option period (see #2 and chart on last page)

b) Commercial Plan (Select one of the following plan types):

[ ] Company-wide or [ ] Division-wide

Total value of projected subcontracts (both large and small businesses) $ _____
Total projected sales $ _____ (Subcontracts Represent [b](4) % of Total Annual Sales)
State separate dollar and percentage goals, expressed in terms of **percentages of the total available subcontracting dollars** listed in the previous section in #1.

**Commercial plans must complete 2a below with 1-year goals, and individual plans must complete 2b below with two separate 5-year goals. Complete only 2a OR 2b, as applicable. Round percentage goals to one decimal place (X.x%).**

2a. **GOALS FOR COMMERCIAL PLANS (1-Year Goals)**

a) Total estimated dollar value and percent of planned subcontracting with **small businesses (SB)** (including ANCs and Indian tribes), veteran-owned small, service-disabled veteran-owned small, HUBZone small, small disadvantaged (including ANCs and Indian tribes), and women-owned small business concerns: b) Total estimated dollar value and percent of planned subcontracting with **veteran-owned small businesses (VO)**: c) Total estimated dollar value and percent of planned subcontracting with **service-disabled veteran-owned small businesses (SDVO)** (Note: This is a subset of veteran-owned): d) Total estimated dollar value and percent of planned subcontracting with **small disadvantaged businesses (SDB)** (including ANCs and Indian tribes): e) Total estimated dollar value and percent of planned subcontracting with **women-owned small businesses (WO)**: f) Total estimated dollar value and percent of planned subcontracting with **HUBZone small businesses (HUB)**:

2b. **GOALS FOR INDIVIDUAL PLANS (Two, Five-Year Goals)**

a) Total estimated dollar value and percent of planned subcontracting with **small businesses (SB)** (including ANCs and Indian tribes), veteran-owned small, service-disabled veteran-owned small, HUBZone small, small disadvantaged (including ANCs and Indian tribes), and women-owned small business concerns:

Base (5-years): $_____ & _____% & 5-Year Option: $_____ & _____% b) Total estimated dollar value and percent of planned subcontracting with **veteran-owned small businesses (VO)**:

Base (5-years): $_____ & _____% & 5-Year Option: $_____ & _____% c) Total estimated dollar value and percent of planned subcontracting with **service-disabled veteran-owned small businesses (SDVO)** (Note: This is a subset of veteran-owned):

Base (5-years): $_____ & _____% & 5-Year Option: $_____ & _____% d) Total estimated dollar value and percent of planned subcontracting with **small disadvantaged businesses (SDB)** (including ANCs and Indian tribes):

Base (5-years): $_____ & _____% & 5-Year Option: $_____ & _____% e) Total estimated dollar value and percent of planned subcontracting with **women-owned small businesses (WO)**:

Base (5-years): $_____ & _____% & 5-Year Option: $_____ & _____% f) Total estimated dollar value and percent of planned subcontracting with **HUBZone small businesses (HUB)**:

Base (5-years): $_____ & _____% & 5-Year Option: $_____ & _____%
3. **PRODUCTS AND/OR SERVICES**
   The types of products and/or services to be subcontracted are:
   - LB: [Redacted]
   - SB: [Redacted]
   - VO: [Redacted]
   - SDVO: [Redacted]
   - SDB: [Redacted]
   - WO: [Redacted]
   - HUB: [Redacted]

4. **GOAL DEVELOPMENT**
   The following method was used in developing the subcontracting goals:
   - [Redacted]
   - [Redacted]

5. **IDENTIFYING POTENTIAL SOURCES**
   The following methods were used to identify potential sources for solicitation purposes (See FAR 52.219-9(d)(5) for examples of methods that may be used.):
   - [Redacted]
   - [Redacted]

6. **INDIRECT COSTS**
   Indirect costs [x] have [ ] have not been included in the dollar and percentage subcontracting goals stated above. (Check one.)
   If "have been" is checked (and you are proposing an individual plan), explain the method used in determining the proportionate share of indirect costs to be incurred with small business (including Alaska Native Corporations and Indian tribes), veteran-owned small business, service-disabled veteran-owned small business, small disadvantaged business (including ANCs and Indian tribes), women-owned small business, and HUBZone small business concerns. Note: *Commercial planholders who choose to...*
include indirect costs will not need to provide the aforementioned explanation because the costs will be applied at 100%.

7. PROGRAM ADMINISTRATOR
The following individual will administer the subcontracting program:

NAME: [Redacted]
TITLE: [Redacted]
ADDRESS: 777 Old Saw Mill River Road
Tarrytown, NY 10591

TELEPHONE: (b) (6)
E-MAIL: (b) (6)

This individual's specific duties, as they relate to the firm's subcontracting program, are as follows:
Manage the [Redacted] and administer processes and plans, set goals, develop strategies to achieve stated goals, enhance procedures, monitor the progress of the program and assign responsibilities, guide the sourcing department to assist in the identification of small and diverse suppliers, and prepare and submit the annual eSRS report December 30th and Small Business Subcontract plan November 30th in a timely manner. Act as mentor and provide extensive counseling and advice to small business entities who are interested in participating in sourcing efforts and to those suppliers who were not awarded Regeneron's business after a sourcing event.

In addition, work with Regeneron's legal team to ensure contracts contain all applicable language regarding small business sourcing opportunities.

8. EQUITABLE OPPORTUNITY
The following good faith efforts (internal and external) will be taken to assure that small business, veteran-owned small business, service-disabled veteran-owned small business, small disadvantaged business, women-owned small business, and HUBZone small business concerns will have an equitable opportunity to compete for subcontracts:

[Redacted]
9. **FLOW-DOWN CLAUSE**
   The offeror agrees that the FAR clause of this contract entitled “Utilization of Small Business Concerns” (52.219-8) will be included in all subcontracts that offer further subcontracting opportunities, and that the Offeror will require all subcontractors (except small business concerns) that receive subcontracts in excess of $700,000 ($1.5 million for construction of any public facility) with further subcontracting possibilities to adopt a subcontracting plan that complies with the requirements of FAR clause 52.219-9 Small Business Subcontracting Plan.

   **NOTE:** See exceptions listed in FAR 52.219-9(j).

10. **REPORTING & COOPERATION**
    The offeror agrees to
    (i) Cooperate in any studies or surveys as may be required;
    (ii) Submit periodic reports so that the Government can determine the extent of compliance by the offeror with the subcontracting plan;
    (iii) After November 30, 2017, include subcontracting data for each order when reporting subcontracting achievements for indefinite-delivery, indefinite-quantity contracts with individual subcontracting plans where the contract is intended for use by multiple agencies;
    (iv) Submit the Individual Subcontract Report (ISR) and/or the Summary Subcontract Report (SSR), in accordance with paragraph (I) of FAR 52.219-9 using the Electronic Subcontracting Reporting System (eSRS) at [http://www.esrs.gov](http://www.esrs.gov). The reports shall provide information on subcontract awards to small business concerns (including ANCs and Indian tribes that are not small businesses), veteran-owned small business concerns, service-disabled veteran-owned small business concerns, HUBZone small business concerns, small disadvantaged business concerns (including ANCs and Indian tribes that have not been certified by SBA as small disadvantaged businesses), women-owned small business concerns, and for NASA only, Historically Black Colleges and Universities and Minority Institutions. Reporting shall be in accordance with 52.219-9, or as provided in agency regulations;
    (v) Ensure that its subcontractors with subcontracting plans agree to submit the ISR and/or the SSR using eSRS;
    (vi) Provide its prime contract number, its unique identity identifier, and the e-mail address of the Offeror’s official responsible for acknowledging receipt of or rejecting the ISRs, to all first-tier subcontractors with subcontracting plans so they can enter this information into the eSRS when submitting their ISRs; and
    (vii) Require that each subcontractor with a subcontracting plan provide the prime contract number, its own unique identity identifier, and the e-mail address of the subcontractor’s official responsible for acknowledging receipt of or rejecting the ISRs, to its subcontractors with subcontracting plans.

11. **RECORDKEEPING**
    The following is a description of the types of records that will be maintained concerning procedures that have been adopted to comply with the requirements and goals in the plan, including establishing
source lists; and a description of the offeror's efforts to locate small business, veteran-owned small business, service-disabled veteran-owned small business, HUBZone small business, small disadvantaged business, and women-owned small business concerns and award subcontracts to them. The records shall include at least the following (on a plant-wide or company-wide basis, unless otherwise indicated):

(i) Source lists (e.g., SAM), guides, and other data that identify small business, veteran-owned small business, service-disabled veteran-owned small business, HUBZone small business, small disadvantaged business, and women-owned small business concerns.

(ii) Organizations contacted in an attempt to locate sources that are small business, veteran-owned small business, service-disabled veteran-owned small business, HUBZone small business, small disadvantaged business, or women-owned small business concerns.

(iii) Records on each subcontract solicitation resulting in an award of more than $150,000 (Note: As of the publication of this template, the threshold of $150,000 has been revised by some agencies via a deviation to either reflect "$250,000" or to reference "the simplified acquisition threshold" rather than referring to a specific dollar amount.), indicating—

(A) Whether small business concerns were solicited and, if not, why not;

(B) Whether veteran-owned small business concerns were solicited and, if not, why not;

(C) Whether service-disabled veteran-owned small business concerns were solicited and, if not, why not;

(D) Whether HUBZone small business concerns were solicited and, if not, why not;

(E) Whether small disadvantaged business concerns were solicited and, if not, why not;

(F) Whether women-owned small business concerns were solicited and, if not, why not; and

(G) If applicable, the reason award was not made to a small business concern.

(iv) Records of any outreach efforts to contact—

(A) Trade associations;

(B) Business development organizations;

(C) Conferences and trade fairs to locate small, HUBZone small, small disadvantaged, service-disabled veteran-owned, and women-owned small business sources; and

(D) Veterans service organizations.

(v) Records of internal guidance and encouragement provided to buyers through—

(A) Workshops, seminars, training, etc.; and

(B) Monitoring performance to evaluate compliance with the program's requirements.

(vi) On a contract-by-contract basis, records to support award data submitted by the offeror to the Government, including the name, address, and business size of each subcontractor. Contractors having commercial plans need not comply with this requirement.

12 & 13. UTILIZATION OF SMALL BUSINESS CONCERNS USED IN BID/PROPOSAL

12. The offeror agrees to make a good faith effort to acquire articles, equipment, supplies, services, or materials, or obtain the performance of construction work from the small business concerns that it used in preparing the bid or proposal, in the same or greater scope, amount, and quality used in preparing and submitting the bid or proposal. Responding to a request for a quote does not constitute use in preparing a bid or proposal. The Offeror used a small business concern in preparing the bid or proposal if—

(i) The Offeror identifies the small business concern as a subcontractor in the bid or proposal or associated small business subcontracting plan, to furnish certain supplies or perform a portion of the subcontract; or

(ii) The Offeror used the small business concern’s pricing or cost information or technical expertise in preparing the bid or proposal, where there is written evidence of an intent or understanding that
the small business concern will be awarded a subcontract for the related work if the Offeror is awarded the contract.

13. The Contractor agrees to provide the Contracting Officer with a written explanation if the Contractor fails to acquire articles, equipment, supplies, services or materials or obtain the performance of construction work as described in (12) above. This written explanation must be submitted to the Contracting Officer within 30 days of contract completion.

14. **SUBCONTRACTOR DISCUSSIONS WITH CO**

The Contractor agrees not to prohibit a subcontractor from discussing with the Contracting Officer any material matter pertaining to payment to or utilization of a subcontractor.

15. **PROMPT PAYMENT OF SMALL BUSINESS SUBCONTRACTORS**

The Contractor agrees to pay its small business subcontractors on time and in accordance with the terms and conditions of the underlying subcontract and notify the contracting officer when the prime contractor makes either a reduced or an untimely payment to a small business subcontractor (see FAR 52.242-5).

*Please note that VA FSS will only accept authenticated digital signatures and scanned copies of documents with wet signatures.*

Plan Approval Signature (Government Official)  [signature]
Typed Name of Government Approver  [name]
Date Approved  [date]
## COMMERCIAL PLANS: SUMMARY OF GOALS

This page is for *commercial plans ONLY*.

Entries below should match your responses in #1 and #2a at the beginning of the template.

Round percentages to one decimal place (X.x%) and dollar figures to the nearest whole dollar.

<table>
<thead>
<tr>
<th>Prior Year Goals</th>
<th>Prior Year Achievements*</th>
<th>Current Goals</th>
</tr>
</thead>
</table>
| **1. Total Subcontracting Dollars**  
(both large & small businesses) | $ (b) (4) | $ (b) (4) | $ (b) (4) |
| **2a. Small Business Dollars**  
SB Percent of Line 1 | $ (b) (4) | $ (b) (4) | $ (b) (4) |
| **2b. Small Veteran-owned Dollars**  
VO Percent of Line 1 | $ (b) (4) | $ (b) (4) | $ (b) (4) |
| **2c. Service-Disabled Veteran-Owned Dollars**  
SDVO Percent of Line 1 | $ (b) (4) | $ (b) (4) | $ (b) (4) |
| **2d. Small Disadvantaged Dollars**  
SDB Percent of Line 1 | $ (b) (4) | $ (b) (4) | $ (b) (4) |
| **2e. Small Women-owned Dollars**  
WO Percent of Line 1 | $ (b) (4) | $ (b) (4) | $ (b) (4) |
| **2f. HUBZone Small Business Dollars**  
HUB Percent of Line 1 | $ (b) (4) | $ (b) (4) | $ (b) (4) |

* If total prior year contract achievements are not available, use actual figures and estimate/prorate balance. Achievements based on Government’s Fiscal Year while Goals are based on Company’s Fiscal Year.
November 30th, 2020

Department of Veterans Affairs
National Acquisition Center (049A1F1)
P.O. Box 76, 1st Avenue North of Cermak Road, Building 37
Hines, IL 60141

To Whom It May Concern,

This letter accompanies our proposal for a Small Business Sub-Contracting Plan ("SBSP"). It is our intention to identify targets for the 2021 fiscal year to reflect realistic and attainable goals for our company. For the purposes of the FY2021 SBSP, Regeneron projects an estimated total value of subcontracts to be (b) (4).

As such, Regeneron proposes the following percentage goals for FY 2021:

- Small Business: (b) (4)%
- Veteran Owned Small Business: (b) (4)%
- Service Disabled Veteran Owned Small Business: (b) (4)%
- Small Disadvantaged Business (SDB): (b) (4)%
- Small Woman Owned Business: (b) (4)%
- HUB Zone Small Business: (b) (4)%

Please contact me with any questions or comments, that you may have.

Respectfully Submitted,